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Magnesium’s potential to degrade completely in vivo with safe corrosion byproducts make it a 
promising biomaterial for use in a wide array of implants from orthopedic fixation devices that do not 
require a removal surgery to peripheral nerve guides that degrade away after regeneration.  However, a 
few issues need to be addressed before widespread clinical use can be realized.  Firstly, Mg often 
degrades too rapidly in vivo. Rapid degradation can result in the mechanical instability and gas bubbles 
that may separate the implant from the tissue. Secondly, Mg implants lack the ability to combat potential 
infection and the inflammatory foreign body response. Lastly, Mg alone lacks a versatile functionalization 
method to incorporate tissue specific cues that better guide tissue growth and regeneration. To overcome 
these issues, conducting polymer based coatings with a combination of functionalities in corrosion 
control, drug release, and biofunctionalization are investigated in this thesis. 
A composite coating of conducting polymer poly 3,4-ethylene dioxythiophene (PEDOT) doped 
with Graphene Oxide (GO) has been developed for improving Mg implant performance for applications 
such as orthopedic fixation, stents, and peripheral nerve regeneration.  The PEDOT/GO coating decreased 
Mg corrosion throughout 22days of immersion in a phosphate buffered solution.  Corrosion protection is 
attributed to an initial passive barrier followed by electrochemical coupling of the coating with the Mg to 
from a more protective Mg phosphate layer.  Additionally, anti-inflammatory drug Dexamethasone was 
incorporated into the PEDOT/GO film and it was shown that Mg corrosion current could drive drug 
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release.  Lastly, the carboxylic acid groups of the GO sheets exposed at the surface of the PEDOT/GO 
coating were used to immobilize multiple bioactive molecules. Specifically, immobilized poly ethylene 
glycol (PEG) prevented both bacterial and fibroblast attachment, while nerve growth factor (NGF) 
attachment increased neurite sprouting from PC12 cells.  These results suggest that the PEDOT/GO 
coating has the potential to be a versatile coating that can provide corrosion protection and add 
biologically relevant cues to the Mg implant.  
 vi 
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1.0  INTRODUCTION 
Implantable medical devices have become a standard in the current healthcare system.  From 
pacemakers to deep brain stimulators, implanted devices have improved the lives of countless 
patients. However, for certain applications, continual presence of the device is not ideal, due to 
chronic inflammation, the foreign body response, and device specific issues such as increased 
thrombogenicity and restenosis for stents and potential metal particulate toxicity from current 
orthopedic materials. For these implantable devices that are only temporarily needed, the 
requirement of surgical implant removal once the tissue has healed minimizes their current 
applications.  Making a temporary device out of biodegradable materials would eliminate the 
need to surgically remove these devices and consequently increase device implementation as 
well as improve patient outcomes.  To accomplish this, a variety of degradable materials 
including polymers and ceramics have been developed, however, Magnesium’s (Mg) superior 
mechanical properties and safe degradation byproducts, provided the corrosion rate is controlled, 
make it a continually promising material.  Mg corrodes naturally in vivo and results in safe 
degradation products provided the corrosion rate is appropriately controlled.  Mg devices such as 
stents, orthopedic fixation screws and plates, and nerve guides provide the opportunity to 
promote proper patient healing without the need for surgical intervention to remove the device 
once its presence is no longer required.  Additionally, in vivo device degradation decreases 
potential complications of long-term device presence such as restenosis and chronic 
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inflammation.  If the corrosion rate of Mg is properly controlled, these Mg devices could be 
designed in such a way that they only exist for the period the specific tissue needs to regenerate 
and following this period they degrade away safely in the body.  This thesis describes use of 
conducting polymers for corrosion control and improvement of Mg implant interactions with 
native tissue.    
1.1 MAGNESIUM AS A DEGRADABLE BIOMATERIAL 
1.1.1 Biocompatibility and Biodegradation 
Magnesium is an extraordinarily promising material for use in biomedical implants due to a 
multiple factors.  Firstly, Mg is considered an essential human nutrient[1]. Mg is the fourth most 
abundant cation in the human body and has been shown to be present at different concentrations 
in nearly all cells[2, 3].  The recommended dietary allowance, the average daily intake sufficient 
to meet the nutritional needs of ~98% of healthy individuals, of Mg for adults is 300-400mg[4]. 
The binding of Mg to ATP is required for energy generation[5].  Mg interacts with nucleic acids 
in a variety of ways and is required in the synthesis of DNA[6, 7].   Mg is utilized in at least 300 
enzymes that are involved in a wide variety of biochemical processes that dictate things such as 
neural activity, muscular contraction, and proper blood glucose and pressure[6].  Magnesium 
also facilitates membrane transport of additional important ions calcium and phosphorus[8].  
This excessive presence of Mg in the human body lends to the expectation that Mg implants will 
be an exceptionally biocompatible material.  
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In addition to its prevalence in the human body, Mg has the potential to completely 
corrode in vivo without toxic side effects.  When placed in vivo, the corrosion of Mg proceeds as 
follows. 
2H2O + 2e-  H2 + 2OH- (cathodic)       (1) 
Mg  Mg2+ + 2e- (anodic)        (2) 
Mg +2H2O  Mg2+ + OH- + H2 (complete reaction)     (3) 
Here the anodic dissolution of Mg (equation 2) generates electrons that reduce water 
through the cathodic reduction of H2O (equation 1).    The complete reaction (equation 3) results 
in the formation of hydrogen gas, hydroxide ions, and Mg2+ ions.  Provided the Mg corrosion is 
slow enough, the hydrogen gas is free to diffuse away through the tissue[9].  The hydroxide ion 
will either be buffered by the body’s many buffering systems or will react with the Mg2+ ions to 
form Mg hydroxide (equation 4). 
Mg2+ + 2OH-  Mg(OH)2        (4) 
Mg(OH)2 is insoluble and  will be deposited on the surface of the corroding magnesium.  
Mg(OH)2 has a porous and amorphous morphology that does not provide a significant 
improvement in corrosion protection[10, 11].  In vivo this Mg(OH)2 layer is easily converted by 
the chloride ions in the body to a soluble MgCl2[1, 12, 13]. This corrosion product can be 
excreted through urination minimizing potential toxicity issues as the implant degrades[14, 15].  
This process of in vivo degradation resulting in safe byproducts Mg2+, OH-, and hydrogen is one 
of the main benefits of using Mg as an implant material. 
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1.1.2 Mechanical properties of Mg 
The superior mechanical properties of Mg are also alluring for implementation as a biomedical 
implant.  Mg and its alloys have a Young’s moduli of around 41-45 GPa and densities of around 
1.74-2 g/cm3 which outperform current degradable polymers such as poly L-lactic acid(PLA), 
Polyglycolic acid(PGA), and the combinations of PLA and PGA which have young’s moduli of 
2.5-6.5 GPa and a specific densities of 1.24-1.61 g/cm2[3, 16, 17].  This gives Mg a superior 
strength to weight ratio advantage over current degradable polymers making it a more viable 
option for structures like stents.  Also Mg’s mechanical properties match those of bone, young’s 
moduli 3-20 GPa and density 1.8-2.1 g/cm2, much more closely than current orthopedic 
biomaterials such as Ti (110-117 Gpa & 4.4-4.5 g/cm2), Co-Cr alloy (230 GPa & 8.3-9.2 g/cm2), 
and stainless steel (189-205 GPa & 7.9-8.1 g/cm2)[15].  This close mechanical match between 
Mg and bone has the potential to minimize stress shielding observed with current orthopedic 
implant metals[3, 15].   
1.1.3 History as a biomedical material 
The first use of Mg in medicine was in 1878 when physician Edward C. Huse used Mg wire, 
originally designed for pyrotechnics and early photography, as ligatures to stop bleeding in 
human patients[18].  Following Huse, Austrian physician Dr. Erwin Payr pioneered the testing of 
magnesium for multiple applications starting in 1892[18].  Payr tested Mg structures for 
connection of vessel antamosis, as well as use of screws, plates, and pegs for orthopedic fixation 
and a variety of general surgery closure and suture applications.  Payr also used Mg for the 
connection of nerves during neurorrhaphy.  Early issues with Mg wires that limited their use 
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resulted from the Mg being brittle and their breaking when tied in a knot.  Investigators explored 
a variety of alloys to improve the ductility of these Mg wires.  Following Payr’s work, 
researchers in the 20th century continued to test various Mg alloys for a multitude of applications 
with varied success.  In 1917 Andrews tested Mg clips as substitutes for ligatures for wound 
closure and suggested while it safely degrades, the degradation is too rapid and the mechanical 
properties of Mg are not sufficiently strong[19]. In the 1930s Verbrugge experimented with the 
use of Mg alloys as plates bands and screws[18].  In 1951 Stone & Lord investigated the ability 
of Mg-Al alloy wires for clotting aneurisms[20].  In 1981 Hussel et al looked at the degradation 
rate of Mg rods in both rat and rabbit subcutaneously and intramuscularly[21].  Of all the work 
completed in the late 19th and throughout the 20th century, while Mg showed it could be a 
valuable tool to act as a degradable fixation device, researchers noted rapid degradation and a 
buildup of gas bubble pockets surrounding the degrading device[18]. 
1.1.4 Mg modifications to improve performance 
To realize the goal of a fully degradable implant material where the corrosion rate can be 
controlled and with minimal generation of hydrogen gas, many techniques have been employed.  
These involve alloying Mg with other elements, generating different surface coatings, or 
applying organic coatings on top of the Mg.   
1.1.4.1 Mg Alloys 
Alloying Mg with different elements can improve corrosion resistance, ductility, as well as 
mechanical strength[11, 22-27].  These alloys, frequently taken from the aerospace and 
automotive industries, often use elements that are considerably more toxic than Mg itself such as 
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aluminum and rare earth elements.  While Mg alloys with these elements can present favorable 
mechanical properties and corrosion rates, the concern for toxicity of the alloying elements upon 
corrosion has minimized their use in biomedical applications.  To address the biocompatibility 
concerns, elements that are considered less toxic have been recently investigated[28-32].  These 
include elements like essential nutrients calcium, zinc, and manganese, as well as potentially 
essential metals that are used in other biomedical applications like Strontium, Tin, and 
Silicon[1].  A wide variety of Calcium (Ca) based alloys have been investigated. Mg-Ca binary 
alloys have shown good mechanical properties as well as biocompatibility[33].  Zinc is also 
considered to be a biocompatible metal[34].  Mg-Zn alloys have improved mechanical properties 
as well as a decreased corrosion rate[35, 36].  Manganese alloys of Mg have been shown to 
decrease the effects of impurities on Mg, decreasing the damaging effects of galvanic coupling 
with impurities and consequently decreasing corrosion rates[36, 37].  Silicon, while having low 
solubility, has been reported as an optimal alloy for improving Mg’s yield strength and ultimate 
tensile strength[38].  Mg Zirconium alloys have also improved Mg’s mechanical properties as 
well as resulted in a 50% decrease in corrosion rate[38].  While binary alloys of Mg minimize 
the potential for corrosion byproduct cytotoxicity, Mg alloys with many different combinations 
of alloying elements have been tested to further improve corrosion resistance and mechanical 
properties[17, 32, 36, 39-42].  Despite the potential issues associated with the release of alloying 
elements during corrosion, some companies have received the CE mark for use of their 
proprietary Mg alloys in biomedical applications. Syntellix AG received the CE mark for their 
Mg based screw Magnezix® in 2013, and Trans Luminal Technologies LLC received the CE 
mark in 2014 for their Mg based vascular closure device Velox CD™ [43, 44].  In summary, 
alloying represents a promising way to improve Mg performance for biomedical applications.  
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1.1.4.2 Conversion coatings 
In addition to alloying, multiple surface treatments have been tested to further adjust the 
corrosion rate of Mg.  These include conversion coatings that are created by immersing the Mg 
in a salt bath to facilitate specific corrosion products via the inherent corrosion of Mg.  The most 
simple conversion coating is that of alkali treatment where the inherent MgO and Mg(OH)2 
surface products are further altered[45].  These coatings show an initial decrease in corrosion 
rate but can be easily broken down by Cl in the body[2].   Calcium phosphate coatings as well as 
hydroxyapatite coatings have been investigated due to their similarity to bone[46-48]. Fluoride 
treatments are also of interest to orthopedic applications due to improved bone interactions[49, 
50].  Fluoride conversion coatings have shown improved corrosion resistance on both pure Mg 
and Mg alloys[51-53].  These and a variety of other conversion coatings have been investigated 
on Mg alloys as well as pure Mg, however corrosion protection is still inadequate[2, 54-57].   
Further techniques involve electrochemical anodization to generate surface coatings with 
improved properties. Anodization of Mg samples takes conversion coatings one step further in 
that, in addition to facilitating a corrosion product by immersing the Mg in different media, an 
electrical potential is applied which can change the morphology and structure of the deposited 
corrosion layer.  Anodization in basic solutions results in the growth of a more stable variant of 
the MgO and Mg(OH)2 layer[58, 59]. Calcium phosphate and hydroxyapatite coatings have also 
been deposited on Mg substrates through anodization[60, 61].  Another anodization paradigm 
used is plasma electrolytic oxidation (PEO), or microarc oxidation, where anodization is 
conducted above the breakdown potential resulting in films that are generally more protective 
than conversion coatings[2].  PEO treatments in biologically relevant media, Hanks solution and 
simulated body fluid, have shown an improvement in corrosion protection as well as improved 
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wear resistance[62-64].  PEO has also been used to deposit calcium phosphate coatings[65-67] as 
well as fluoride coatings[68].  A variety of different coatings have been applied to Mg and its 
alloys through PEO in the effort to improve corrosion and wear performance[69-71]. The benefit 
of anodization and PEO over conversion coatings is that the energy applied during formation 
results in a more dense and uniform film with a complete coverage of the sample that results in 
superior corrosion protection.  
1.1.4.3 Polymer coatings 
Other techniques used to improve Mg corrosion resistance include the application of an 
additional surface coating, commonly a polymer, either degradable or non-degradable.  These 
polymer coatings provide added benefits of potential mechanisms for drug release as well as 
methods for adding functional biomolecules to Mg [2, 72].  Coatings of non-degradable 
poly(ether imide) PEI have improved Mg corrosion resistance[73, 74]. PLGA degradable 
polymer coatings have been effective at slowing Mg corrosion as well as improving Mg alloy in 
vitro interactions with osteoblast-like MC3T3 cells[75].  Applications of other degradable 
polymers PLA and polycaprilactone(PCL) have also shown the ability to improve corrosion 
resistance of Mg and improve cytocompatibility with osteoblasts[76, 77].  Xu and 
Yamamoto[78]  compared Mg coated with PLLA or PCL via spin coating and concluded that 
both coatings improve cytocompatibility while PLLA was better adhered to the Mg substrate. 
Prior to organic coating application, Mg and its alloys are often pretreated with a conversion 
coating or PEO surface treatments to improve the adhesion of these organic coatings[2, 72, 79].  
This dual protection paradigm can combine the corrosion protection of the conversion coating 
and polymer coating in addition to providing a system for drug release and surface 
functionalization. 
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Drug release from these polymer coatings is another potentially powerful technique to 
improve in vivo Mg implant performance.  The most common techniques for drug release is 
diffusion of the drug from the film or release of the drug from the film as the polymer 
degrades[72].  Lu et al [80] deposited PLGA coatings on pretreated Mg which released drug at 
different rates based on the ratio of lactic and glycolic acids. These drug releasing PLGA 
coatings also improved corrosion resistance of the coated Mg.  Mg based stents coated with 
degradable polymer from Biotronic SE & Co. have shown the ability to release paclitaxel and 
degrade away safely[81].  Adjusting the polymer ratios in PLGA coatings on degradable stents 
can tailor the release rate of drugs like paclitaxel[82].  Cross-linked gelatin with degradable 
PLGA drug containing nanoparticles have also been used as a drug releasing platform on Mg 
where the release rate could be controlled through the crosslinking density[83].  Polymer 
coatings also provide loci for further functionalization.  PLLA coatings on Mg allowed for the 
attachment of fibronectin which improved the attachment of MC3T3 osteoblast like cells[84].    
While these different polymer coatings provide a viable method of controlled drug release there 
is minimal corrosion protection. Once the polymer has degraded away, corrosion of the 
underlying Mg substrate proceeds unhindered.  Additionally, these drug releasing coatings do not 
provide an on demand release, once in contact with body fluid, the polymer begins to degrade 
and release the drug.  A drug releasing platform that can respond to changes around the implant 
and release drugs at specific events could help to improve the local tissue response and minimize 
potential toxic side effects of the continual drug delivery of current coatings.   It would be ideal 




Mg has a potential multitude of applications in the biomedical field due to its biocompatibility, 
biodegradation, and superior mechanical properties compared to current biodegradable materials.  
Since the 1870s, Mg materials have been investigated for these applications, however rapid 
degradation and buildup of gas bubbles surrounding the implants have limited the clinical use of 
Mg.  To combat these issues different techniques such as, alloying, conversion coating, 
anodizing, and coating with polymers have been tested.  While promising, these techniques still 
leave room for improvement in terms of biocompatibility and corrosion protection performance.  
In addition, the current techniques have limited abilities to deliver drugs around the implant in an 
on demand way.  Current polymer coatings simply release drug as the polymer is degraded in 
vivo.  A technique that could both control Mg corrosion and provide an on demand method for 
drug release could facilitate the transition of Mg implants from academic research to clinical 
applications.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
1.2 CONDUCTING POLYMERS 
Electro-active conducting polymers (CP) are a unique set of materials that possess both 
conductivity and redox properties.  Since first being reported by Henry Letheby, a British 
chemist, in 1862, CPs have found uses in many applications[85].  Largely developed from the 
1970s onward, CPs have been used in thin film transistors[86], fuel cells[87], super 
capacitors[88], corrosion control[89, 90], and sensors[91, 92].  In addition, CPs have been 
investigated for a wide range of biomedical applications[93-95].  From improving the charge 
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transfer on microelectrodes[96-99], to acting as a controllable drug releasing platform[100-102], 
to facilitating the addition of surface cues[103], CP structure and function have the ability to suit 
many different applications through careful tailoring of the chemistry. 
1.2.1 Polymerization of CP 
CP synthesis is one of the attractive aspects of these unique polymers with the ability to be both 
chemically driven as well as electrochemically driven.  In both instances, oxidation of the 
monomer is followed by free radical polymerization where the new polymer will precipitate out 
of the polymerization solution upon its increase in molecular weight[104].  The chemical 
polymerization method utilizes strong oxidizing agents to facilitate polymerization that are ideal 
for large-scale solution polymerization.  To create a thin film from CPs polymerized with this 
technique, the CP is placed on the sample and the sample is then spun at a consistent speed 
resulting in a thin polymer film.  This technique is good for flat surfaces without much 
topography.  In some cases oxidizing agents have been immobilized on the surface to generate a 
thin film of polymer, however uniformity and thickness are difficult to control making thin films 
of CP difficult to fabricate with chemical polymerization methods[105].  To overcome some of 
the issues associated with chemical polymerization, electrochemical polymerization has been 
investigated.  While limited in that the surface to be coated must be conductive and not effective 
for bulk polymerization, electro-polymerization allows for a more controlled deposition of thin 
films of CPs on more complex geometries.  Electro-polymerization utilizes an oxidizing 
potential on an electrode immersed in a monomer solution.  This potential drives the radical 
polymerization at the surface of the electrode on which the potential is applied resulting in the 
deposition of thin films of the polymer on the surface[105].  This dissertation utilizes this method 
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of electro-polymerization due to its ability to coat the potentially complex geometries of 
structures like stents. 
   Electro-polymerization provides additional control over the deposition parameters in 
that the intensity of the applied potential or current as well as the duration can be carefully 
controlled through the hardware of the electrochemical system.  Electro-polymerization has been 
conducted in three different ways, potentiodynamic, galvanostatic, and potentiostatic each with 
its benefits and drawbacks.  Potentiodynamic involves the sweeping of applied potentials 
between magnitudes that would drive polymerization and those that are too week to drive 
polymerization.  This allows for the deposition of very thin films of CP via one sweep and in 
order to build up a thicker layer multiple cycles are often conducted.  The repeated deposition of 
thin layers of polymer with a wait time in-between, as the potential is not strong enough to drive 
polymerization, allows for the entrapment of solvents and other molecules present in the 
polymerization solution[106]. Entrapped anion and solvent molecules then affect the resulting 
CP in terms of compactness or degree of swelling and electrical performance.  Galvanostatic 
polymerization applies a set current for a set duration in which the current results in a potential 
that is sufficiently intense to drive polymerization.  This constant current method allows for the 
same total charge to be delivered during film creation resulting in the same amount of polymer 
being deposited and consequently films of the same thickness.   Despite the control over the 
current, the potential is free to fluctuate during polymerization resulting in films with differing 
degrees of oxidation and consequently different electrochemical behavior.  Potentiostatic 
methods set the applied potential during polymerization, which prevents over oxidation of the 
CP.  However, the current, and therefor total charge, are allowed to fluctuate making it difficult 
to create coatings of uniform thickness.  To remedy these drawbacks of potentiostatic and 
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galvanostatic polymerization, a method called chronocoulometry uses potentiostatic 
polymerization with built in integrator that allows for the continual calculation of the total charge 
used during the polymerization.  This method allows for precise control of the potential applied 
as well as consistent total charge and resulting film thickness.  This chronocoulometry method 
was used for the polymerizations presented in this thesis due to optimal potential control as well 
as the ability to polymerize multiple films with the same total charge. 
1.2.2 Doping and conductivity of the CP 
Deposition of CP alone results in films with minimal conductivity, however further reducing or 
oxidizing the polymer backbone can improve the conductivity of these polymers to levels of 
metals[105].  This thesis will focus on the further oxidization of the polymer backbone as it is 
accomplished in a one-step electropolymerization where an oxidizing potential is used to both 
drive polymerization and oxidize the polymerized CP backbone.  Oxidation of the polymer 
backbone results in a positive charge on the backbone that, during polymerization, is balanced by 
incorporating negative molecules into polymer film termed ‘dopants’.  These dopants are 
incorporated into the film and associated with the positive charges located on the CP backbone.  
The reaction depicting this polymerization, oxidation, and doping process can be seen in 
equation 5 where HMH is the CP monomer. 
(n+2) HMH   HM(Mn)MH(nx)+ + (2n+2)H+ + (2n + 2 +nx)e-     (5)   
Doping levels of conducting polymers typically fall between 0.25 and 0.4 represented as x in the 
above equation[107].   
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Following doping of the film, CP conductivity is attributed to both the conjugated 
backbone as well as the formation of polarons and bipolarons on the oxidized backbone which 
are neutralized by the dopant molecules.  The conjugated backbone of the CP consists of 
alternating double and single bonded sp2 hybridized atoms with overlapping p-orbitals[105].  
These overlapping p-orbitals result in the formation of π molecular orbitals and the ability to 
share electrons through this continuous supramolecular orbital [108].  Upon further oxidation, 
electric holes are created in the polymer backbone.  Polarons and bipolarons are created by these 
holes upon addition of the dopant. This results in mobile charge carriers consisting of loosely 
localized electrons surrounded by distortion of the lattice on the CP backbone which further 
improves conductivity[109]. 
A unique property of these CPs is their ability to undergo reversible redox reactions.  
After electro-polymerization, the polymer backbone is in an oxidized state with positive charge 
on the backbone and negatively charged dopants trapped in the CP to neutralize this charge.  If a 
reducing potential is then applied to the polymer, the positive charge on the CP backbone can be 
neutralized resulting in no electrostatic force holding the negative dopant in the film.  These 
dopants then have the ability to diffuse out of the film into the surrounding media.  This process 
has been used extensively as a method for controlled drug delivery[101, 102, 110-113].  It has 
also been shown that larger dopants can remain trapped in the film resulting in the intake of 
positive ions to balance the negative charge left behind upon polymer reduction[114].   
1.2.3 Applications of conducting polymers 
The reversible redox properties make CPs useful micro actuators.  Mechanical changes are 
facilitated by the insertion and expulsion of counter ions during reduction and oxidation[115]. 
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Smela et al first showed the ability to use CP redox reactions as actuators by creating bi-layered 
structures of gold and CP[116].  Upon reduction of the polymer, the expulsion of anions, and 
shrinkage of the CP caused the structures to curl.  This was further elaborated to a box design 
where the entire gold/CP box could be opened and closed.  Jager et al used a complex micro 
fabricated structure of gold and CP to create a micrometer sized manipulator[117].  The 
combined actuation of CP gold structures could pick up and move a 100 µm glass bead a 
distance of 250 µm.  In addition to the µmotion of objects, these CP actuators have been used as 
strain sensors [118, 119] and for the detection of acid/base[120].   
Redox properties of CPs have also been used for electrochromic devices where the 
optical properties of the CP are dependent on its redox state.  Devices consisting of layers of 
different CPs have shown fast response times and long-term stability as electrochromic 
devices[121].  These CP electrochromic devices have also shown improvements in bleached vs. 
colored switching time and improved contrast[122, 123].   
CPs have also shown promise as a useful technology for biomedical applications 
including sensors[124, 125], tissue engineering[94, 95, 126-128], and electrodes that interface 
with tissue[96, 97, 113, 129-131].  Conducting polymer morphology is highly dependent on the 
dopant incorporated, however, even small dopants result in a rough surface morphology.  This 
rough surface increases the effective surface area and consequently decreases electrode 
resistance and improves capacitive charge transfer.  The lower resistance provided by CP 
coatings on neural electrodes has been shown to improve the recording of these electrodes[96].  
CPs also facilitate more effective charge transfer through faradaic charge transfer mechanisms.  
For metal electrodes, faradaic charge transfer takes place through the oxidation of the metal 
which can result in electrode damage[129].   CPs on the other hand can facilitate charge transfer 
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through the reduction and oxidation of its backbone that is accompanied by the expulsion and 
incorporation of ions.  This results in improved charge transfer for stimulation electrodes in that 
lower voltages are required to pass the same amount of charge which minimizes potential tissue 
damage from high potentials[99].  Conducting polymers also can improve the tissue reaction to 
implanted electrodes by providing a mechanical buffer between the generally hard electrodes and 
soft neural tissue[132].  The release of entrapped ions during polymer reduction has also been 
investigated as a way to locally deliver drugs to improve tissue reactions around CP coated 
electrodes[110].  Release of anti-inflammatory dexamethasone from CP coated electrodes has 
been used to decrease inflammation around implanted electrodes[98, 133].  Conducting polymers 
also provide mechanisms for functionalization with bioactive molecules that can improve the 
interaction of local tissue with the polymer or be used to elicit specific changes in the local 
tissue[97, 103, 134].   
1.2.4 Summary 
CPs can be deposited on to conducting substrates of different geometries through 
electropolymerization.  This results in a CP film that is both electrically and ionically conductive.  
These CPs can undergo reversible redox reactions where the polymer backbone is reduced and 
the charged dopants are released from the film.  These properties of CPs have resulted in their 
application in a wide variety of application including exploration for many biomedical 
applications.  
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1.3 GRAPHENE AND GRAPHENE OXIDE 
Graphene is a relatively new carbon structure that was first synthesized in 2004 and consists of a 
single atomic layer of carbon arranged in a 2 dimensional honeycomb lattice[135, 136].  This 
unique structure presents a myriad of new properties including exceptional electronic, 
mechanical, and optical properties[137-139].  The properties of graphene are highly dependent 
on the purity and as a result, a variety of methods for developing graphene have been introduced.  
One of the more popular methods is that of chemical exfoliation because it is relatively low cost 
and more easily scaled than other methods.  This process uses strong oxidizing agents to separate 
graphene from graphite resulting in graphene sheets that are highly oxidized referred to as 
graphene oxide (GO)[140].  In an effort to convert GO to graphene, different chemical, thermal, 
and electrochemical treatments have been tested to create reduced GO (rGO) which has similar 
performance characteristics to graphene.  The intermediate GO has also garnered interest due to 
the large number of reactive oxygen functional groups which allow for the addition of different 
chemical groups[140].      
While the exact chemical structure of GO is dependent on its fabrication route and still 
debated, the generally accepted model of GO is that proposed by Lerf-Klinowski[140].  This 
consists of the carbon honeycomb sheet of graphene with dislocations of hydroxyl (C-OH) and 
epoxide (C-O-C) as well as carboxyl (C-O-OH) groups on the edges of the carbon sheet[141].  
This structure provides numerous active sites while also maintaining some areas of sp2 
hybridized domains that can partake in π-π stacking of aromatic rings. Consequently, GO has 
been investigated for a wide range of applications including acting as a catalyst[142], guided 
cancer therapy[143], sensors[144-146], super capacitors[147, 148], electronics[149], and 
solution processing[150] to name a few. 
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Graphene Oxide has also been used as a barrier layer to protect surfaces from corrosion.  
Graphene sheets provide good barriers that prevent corrosion media from reacting with the 
underlying substrate[151-153].  The additional negative charges on the GO can further inhibit the 
corrosion by preventing aggressive negative ions from reaching the surface [154, 155].   
Graphene and Graphene oxide have also seen a great deal of use in the drug delivery 
field[156, 157].  The combination of high surface area, hydrofillicity, presence of aromatic 
regions, and presence of functional epoxy, hydroxide, and carboxyl groups make GO an ideal 
candidate for different drug delivery applications.  Anti-cancer drug doxorubicin showed strong 
bonding with GO sheets through both π-π stacking of aromatic regions and hydrogen bonding 
with the functional groups[158].  GO sheets have also been used to transport aptamers into cells 
for in situ molecular analysis[145].  Functionalization of GO’s reactive groups with polyacrylic 
acid has also facilitated improved loading and release of a chemotherapeutic agents[159]. 
Graphene and GO have seen varying reports on their biocompatibility [160] with some 
researchers suggesting toxicity while others showing varying levels of biocompatibility.  Notably 
the biocompatibility of graphene and GO is heavily dependent on the size of the sheets, the 
concentration of exposure, and purity of the sample[161].  Despite the varying results in reports 
of graphene and GO toxicity, for GO specifically, where the hydroxyl, epoxide, and carboxyl 
groups interrupt the carbon structure, there is evidence that these structures can be degraded in 
vivo.  Phagocytotic cells have shown the ability to uptake GO structures[162], and certain 
enzymes facilitate degradation of the GO sheets[163, 164].  These reports suggest that GO could 
be degraded in vivo with minimal toxicity.  Additionally, the toxicity of graphene and GO 
structures have been markedly reduced through the attachment of additional groups such as 
Polyethylene glycol[160].  
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1.4 CONDUCTING POLYMER AND GRAPHENE COMPOSITES 
With the unique properties of both CP and Graphene, combinations of the two have been 
investigated for multiple applications including batteries[165, 166], super capacitors[148, 167], 
heavy metal removal filters[168, 169], and improved sensors[125, 170] to name a few.  These 
applications often take advantage of the coupling of the electrical properties of Graphene with 
CP to create materials of superior conductivity and increased surface area due to the roughness 
added to CP films when incorporating the Graphene sheets[171].  These high surface area 
electrochemically stable CP/Graphene composites have been explored as super capacitors with 
the ability to have high power densities and high cycle lifetimes[167, 172].  One method of 
creating these films is through the polymerization of CP doped with GO followed by the 
reduction of GO to rGO which has superior electrical properties[171].  CP films doped with GO 
that were subsequently reduced to form CP/rGO films exhibited a high rate of charge transfer 
and excellent cycling stability when used as a cathode for a lithium ion battery[165].  In addition, 
high surface area CP/rGO composites have been shown to be effective at adsorbing heavy metals 
for removal during water treatment[168, 169].   Our lab has taken advantage of the improved 
properties when incorporating GO into CP coatings for sensors.  CP/GO sensors showed 
improved Dopamine detection sensitivity due to improved electrochemical properties of the 
sensor as well as electrostatic interactions between the dopamine molecule and the CP/GO 
surface[125].  The superior electrochemical properties of CP/Graphene composites result in a 
wide array of potential applications.  
 20 
1.5 THESIS ORGANIZATION 
The work described in this thesis explores the use of a CP/GO composite coating for improving 
the properties of Mg for biomedical implants.  While much work has been done utilizing CPs on 
other metals, there has been little exploration of CPs on Mg.  A composite coating of CP/GO on 
Mg will be fabricated and investigated. The coating’s ability to satisfy the current needs for 
improvement of Mg implants including, corrosion control, drug delivery, and improved tissue 
reaction will be examined.  This effort seeks to provide insight into technology that can help Mg 
devices transition clinical use.   
Chapter 1 will focus on the use of CP and GO composite as a method of decreasing 
corrosion on Mg substrates.  Both CPs and GO have shown individual abilities to prevent 
corrosion, this work investigates the synergistic effect of combining the two.  Firstly this work 
will describe the electrochemical polymerization method determined to deposit the CP/GO film 
on the Mg surface.  Then the corrosion protection of the film will be investigated through 
multiple methods to determine the mechanisms of corrosion control.  Lastly the effect of the 
CP/GO film on cytotoxicity of Mg samples will be assessed. 
 Chapter 2 will focus on the use of CP/GO films as a platform for self-powered drug 
release.  Here, Anti-inflammatory drug dexamethasone (Dex) will be incorporated into the 
CP/GO film on Mg developed in Chapter 1.  The ability of the CP/GO/Dex film on Mg to release 
drug will be investigated.  Different methods of controlling drug release from the CP/GO/Dex 
films will be explored through the use of Mg corrosion current as a source of electrons to reduce 
the polymer backbone and facilitate drug release. 
 Chapter 3 will begin to explore the ability to use CP/GO films as a method to add surface 
functionalized cues on to Mg.  The exposed carboxyl groups on the GO protruding from the CP 
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film will be used to functionalize bioactive molecules on the surface of CP/GO coated Mg.  The 
presence of the functionalized moiety on the surface will be confirmed and the ability of this 
surface cue to elicit a cellular response will be evaluated. 
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2.0  POLY (3,4-ETHYLENEDIOXYTHIOPHENE) GRAPHENE OXIDE 
COMPOSITE COATINGS FOR CONTROLLING MAGNEISUM IMPLANT 
CORROSION  
2.1 ABSTRACT 
Magnesium (Mg) is a promising biodegradable implant material because of its appropriate 
mechanical properties and safe degradation products.  However, in vivo corrosion speed and 
hydrogen gas production need to be controlled for uses in biomedical applications. Here we 
report the development of a conducting polymer 3,4-ethylenedioxythiphene (PEDOT) and 
graphene oxide (GO) composite coating as a corrosion control layer.  PEDOT/GO was 
electropolymerized on Mg samples in ethanol media. The coated Mg samples were subjected to 
various corrosion tests. The PEDOT/GO coating significantly reduced the rate of corrosion as 
evidenced by lower Mg ion concentration and pH of the corrosion media. In addition, the coating 
decreased the evolved hydrogen. Electrochemical analysis of the corroding samples showed a 
more positive corrosion potential, a decreased corrosion current, and an increase in the 
polarization resistance.  PEDOT/GO corrosion protection is attributed to three factors; an initial 
passive layer preventing solution ingress, buildup of negative charges in the film, and formation 
of corrosion protective Mg phosphate layer through redox coupling with Mg corrosion. To 
explore the biocompatibility of the coated implants in vitro, corrosion media from PEDOT/GO 
 23 
coated or uncoated Mg samples were exposed to cultured neurons where PEDOT/GO coated 
samples showed decreased toxicity. These results suggest that PEDOT/GO coating will be an 
effective treatment for controlling corrosion of Mg based medical implants. 
2.2 INTRODUCTION 
High strength to weight ratio, excellent mechanical properties, and biodegradability makes 
magnesium attractive for a variety of biomedical implant applications[11, 173, 174]. The ability 
of Mg implants to completely degrade in the body prevents the need for implant removal surgery 
and minimizes the side effects due to the chronic presence[3, 39, 175-177]. In vivo corrosion of 
Mg implants result in harmless byproducts, granted that the corrosion rate is appropriately 
controlled[2, 174, 175, 178]. In addition, Mg is essential in numerous biological processes and 
increased levels of Mg have been shown to be beneficial to osseointegration as well as neural 
protection and regeneration[176, 179-181]. Mg’s mechanical properties are also superior to 
current biodegradable polymers[16].   Despite the promise of Mg as a biodegradable implant 
material; there have been multiple reports on rapid in vivo corrosion of Mg [9, 11, 17, 18, 39, 41, 
42, 182, 183]. Rapid degradation results in premature mechanical failure and can lead to harmful 
buildup of corrosion products, such as hydroxide ions, which increases the local pH, and 
hydrogen gas that can result in gas bubble formation around the implant.  In order to prevent 
such uncontrolled and rapid in vivo degradation, many approaches have been investigated to 
control corrosion, including alloying, coatings, and surface treatments.   
 Conducting polymer (CP) coatings have shown promise in their ability to increase 
corrosion resistance of metals.  CPs can be electropolymerized directly on metal surface along 
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with appropriate dopant molecules resulting in a conductive and electroactive film that can have 
unique redox reactions with the underlying metal[114].  With multiple different types of CPs and 
a greater number of dopants, many mechanisms have been proposed to explain CP corrosion 
control.  These mechanisms have been thoroughly reviewed elsewhere [89, 90, 114] and include: 
a barrier layer, ennobling, anodic protection, formation of a modified CP metal interface, 
facilitation of a protective oxide, shifting of the electrochemical interface, and use of dopant 
released from the CP to facilitate a more corrosion resistant surface layer.  Some research also 
suggests that CPs can electrochemically protect exposed areas of the substrate and act as a self-
healing coating[184, 185].  
 In addition to CPs, graphene and graphene oxide (GO) have been shown to 
provide effective corrosion control.  Layers of graphene sheets alone can act as a barrier to 
prevent corrosion[151-153]. GO sheets, due to negatively charged functional groups, can repel 
anions that normally facilitate corrosion[154]. We hypothesize, that when GO is coupled with 
the CP coating as immobile anionic dopant, additional corrosion protection benefits may be 
obtained. As the positive backbone of the CP is reduced via the electrons generated by metal 
corrosion, large dopants will remain physically trapped in the film resulting in a net negatively 
charged film. Such an effect has been previously reported with polypyrrole CP doped with 
dodecylsulfate [114].  
 The aforementioned corrosion studies involving conducting polymers have been mostly 
focused on metals such as aluminum and stainless steel, while few have investigated the use of 
CPs to control Mg corrosion[186, 187]. In our previous work we show that PEDOT film 
electrodeposited on Mg surfaces in ionic liquid reduced the corrosion current[186]. In this work 
we developed a method to electrochemically polymerize poly 3,4-ethylenedioxythiophene 
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(PEDOT) doped with GO on Mg to utilize the synergistic properties of both CP and GO. The 
effect of the PEDOT/GO coating on Mg corrosion was evaluated and the mechanism of 
corrosion protection investigated.  Additionally, the effect of the coating on cellular toxicity of 
Mg was assessed with primary neuron cultures. 
2.3 MATERIALS AND METHODS 
2.3.1 Materials 
Single layer graphene oxide sheets were purchased from Cheap Tubes (Cambridgeport, VT).  
200 proof ethanol was purchased from Decon Labs Inc. (King of Prussia, PA).  Magnesium 
ribbon ≥99.5% (3 mm wide x 0.2 mm thick), 3,4-Ethylenedioxythiphene (EDOT) monomer, 
methanol, laminin (from Engelbreth-holm-swarm murine sarcoma basement membrane), and 
nitrocellulose were purchased from Sigma-Aldrich.  PBS 10x concentrate (136 mM NaCl, 2.7 
mM Potassium chloride, 10 mM Phosphate Buffer) was purchased from EMD Millipore 
(Billerica, MA) and diluted using de-ionized water from a Millipore Milli-Q system.  StanBio 
Liquicolor Magnesium Test and Live Dead stain were purchased from Fisher Scientific.  
Conductive silver paint was purchased from Electron Microscopy Sciences (Hatfield, PA).  Two 
part epoxy was purchased from Leco (St. Joseph, MI). Glutamax 100x, B27 supplement, and 
Neurobasal media for neuron culture were purchased from Gibco (Grand Island, NY).  Primary 
neurons were isolated from e18 rat cortices from Brain Bits (Springfield, IL). 
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2.3.2 Polymerization of the PEDOT/GO film 
GO was added to ethanol at a concentration of 10 mg/ml and the resulting solution was sonicated 
for 30 minutes in a bath sonicator FS110H (Fisher Scientific).  Following sonication, 20 µl/ml 
EDOT and 35 µl/ml deionized water were added and dissolved into the GO ethanol solution to 
create the polymerization solution. Magnesium ribbon was cut into 2 cm long strips, rinsed with 
ethanol, and blotted dry.  Polymerizations, and all electrochemical measurements, were 
conducted on a Gamry Potentiostat FAS2/Femtostat using Gamry Framework Software 
(Warminster, PA).  Polymerization consisted of a two-electrode system with Mg ribbon working 
electrode and a gold counter/reference electrode.  Polymerization was conducted in 300 µl of 
fresh polymerization solution and a potential of 0.6 V vs. counter was applied until a charge of 
10 mC was reached.  Coated length was 9 mm (Fig.2-1).  Following polymerization, electrodes 
were gently dipped in ethanol then dried at -20oC for two days, followed by drying at 3oC for one 
day.  Following this drying process, the PEDOT/GO forms a thin adherent black film on the Mg 
ribbon.  Samples were stored at ambient temperature following drying process. 
 
Figure 2-1: Mg ribbon following polymerization 
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2.3.3 Tafel Scan 
A three-electrode system was utilized with Ag/AgCl reference, platinum counter, and Mg 
working electrode.  Coated or uncoated samples were immersed 5mm into PBS for the scan.  
This ensured only the coated portion of the PEDOT/GO sample was exposed to the PBS (Fig. 2-
2).  Open circuit potential (OCP) was recorded for 600 s, or until it reached a stability of 0.05 
mV/s.  Following OCP determination, the sample was scanned from -0.25 V to +0.25 V vs. 
OCP.  This scan provides a current vs. voltage graph displaying the anodic and cathodic half 
reactions.  The low current valley in the graph is the position where the anodic and cathodic half 
reactions are in equilibrium.  The potential where this occurs is the corrosion potential (Ecorr). 
Additionally, the current where the half reactions are in equilibrium can be extrapolated from the 
linear portions of the cathodic and anodic arms of the tafel scan.  The point of intersection of 
these linear extrapolations is the corrosion current (icorr). 
 
Figure 2-2: Tafel scan immersion 
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2.3.4 Long term corrosion tests (pH, Mg ion, OCP, and EIS) 
PEDOT/GO coated and uncoated Mg samples were electrically connected using conductive 
silver paste and copper wire to the back of the Mg sample (Fig. 2-3).  Samples were then 
mounted in epoxy only leaving 5mm length exposed.  This resulted in a fixed area of the sample 
being exposed to the corrosion solution, with only coated portions being exposed for 
PEDOT/GO samples.  Corrosion was conducted in PBS using 20 ml/cm2 media volume to 
surface area ratio.  Each day samples were transferred to fresh PBS and OCP and 
Electrochemical Impedance Spectroscopy (EIS) measurements were conducted in fresh PBS.  
Mg ion concentration and pH measurements were taken from the PBS of the previous day. 
 
Figure 2-3: Mg samples for long term corrosion tests 
2.3.4.1 OCP and EIS 
In fresh PBS, a three-electrode system was used to measure the OCP and EIS with an Ag/AgCl 
reference, platinum counter, and Mg working electrode.  OCP was recorded for 600 s, or until it 
reached a stability of 0.05 mV/s.  Following OCP, EIS was taken from 100 kHz to 0.1 Hz with 
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an applied potential of 0 V vs. OCP and a voltage amplitude of 10 mV.  Equivalent circuit 
analysis was conducted using Gamry Echem Analyst software. 
2.3.4.2 pH and Mg ion concentration measurement 
The pH of the daily corrosion media was measured using Fisher Scientific Accumet Ab15. 
Magnesium Ion analysis was conducted using StanBio Magnesium Liquicolor (Xylidyl Blue 
assay).  200 µl of the liquicolor assay was added to each well 96 well plate. Corrosion solution 
was diluted in half with PBS.  Three 10 µl samples were taken from each dilute corrosion 
solution and placed into individual wells containing the liquicolor solution and gently mixed.  
Samples were allowed to react at room temperature for 10 minutes.  Absorbance at 520 nm was 
then tested, after ensuring there were no bubbles in the wells, using a Spectromax M5 
spectrophotometer. 
2.3.5 Hydrogen evolution measurement 
PEDOT/GO coated Mg and uncoated Mg samples were mounted in epoxy on glass microscope 
slides leaving 5 mm of the sample exposed.  Samples were then placed in a 2 L crystallization 
dish filled with PBS.  2 ml plastic pipettes were modified so that the tip was closed and the 
opposite end was flared out.  These pipettes were filled with PBS and placed over the corroding 
Mg samples.  Hydrogen evolved from the samples was collected at the top of the pipette 
allowing for quantification of the total volume of evolved hydrogen gas. 
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2.3.6 SEM and EDX analysis 
SEM analysis was conducted using a Jeol JSM 6330F SEM.  Accelerating voltage was 3kV 
unless otherwise noted.  Samples were analyzed before corrosion and after 22 days of corrosion 
in PBS, refreshing PBS every day.  Following corrosion, samples were rinsed in DI water 
followed by ethanol rinse and air-dry, and stored in a desiccator until imaging.  Coating integrity 
and surface morphology of coated and uncoated samples were analyzed.  Due to lack of EDX 
analysis capability on JEOL JSM 6330F, further chemical analysis was conducted on a Jeol 
JSM6510 SEM using an Oxford Instruments X-ray analyzer and Inca Software.  Working 
distance was 10 mm and accelerating voltage was 20 kV for elemental analysis.  Elemental 
identification was conducted automatically through the Inca EDX software. 
2.3.7 Neuron culture 
Coated and uncoated Mg samples were placed in culture media (Neurobasal media, 10% Horse 
serum, 2 mM L-alanyl-L-glutamine, 4 ml b27 50x per ml media, and 1% PennStrep) at a surface 
area to volume ratio of 1.25 ml/cm2.  Corrosion was conducted in a cell culture incubator at 37oC 
and 5% CO2.  Following corrosion for 24 or 72 hours, different amount of corrosion media were 
added to neurons cultures.   
 96 well plates were pre-coated with nitrocellulose, cast from 1 cm2/ml methanol solution, 
followed by laminin (40 µl/ml) adsorption then rinsed with PBS.  Following pretreatment, 
primary neurons from e18 rat cortices were dissociated via trituration and were plated at 30,000 
cells/well.  Neurons were allowed to grow in unaltered media for 1 day.  After one day, the 
 31 
media was replaced with non-dilute (100%) corrosion media as well as corrosion media diluted 
to 50 and 10% with fresh culture media.   
2.3.7.1 LDH Assay 
Following exposure for 24 hours, cytotoxicity was also assessed using the LDH assay.  50 µl cell 
supernatant was removed and combined with 50 µl assay reaction solution.  Reaction proceeded 
for 30 minutes at room temperature followed by addition of 50µl of the assay stop solution.  
Absorbance was measured at 490 nm (for LDH) and 680 nm (for background) using a Molecular 
Device Spectromax M5 plate reader. 
2.3.7.2 Live dead staining 
Following exposure to corrosion solution, media was removed and replaced with staining 
solution 2 µM calceinAM and 2 µM ethidium homodimer-1 in PBS.  After 10 min of incubation, 
images were taken on a Leica DMI 4000B inverted scope.  Counting was conducted with ImageJ 
manually using ‘Cell Counter’ add-on by Kurt De Vos. 
2.3.8 Statistics 
Statistical analysis was conducted using a two-tailed Student’s T-Test.  Significance is 
considered p<0.05.  Data is represented as mean (± SEM). 
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2.4 RESULTS 
2.4.1 Film formation 
Electropolymerization of PEDOT requires an oxidizing potential that can drive Mg corrosion.  
To minimize this corrosion and increase PEDOT/GO film adhesion, polymerization was 
conducted in ethanol.  Initially, pure ethanol was utilized as the sole solvent as it does not 
facilitate Mg corrosion[188]. However, film growth was not achieved.  Previous reports of 
polymerization in non-aqueous media noted the effect of small amounts of water on polymer 
growth[189-191].  Addition of water to the polymerization solution serves to decrease the 
electrostatic repulsion of the radical mer units during polymerization by increasing the 
permittivity of the polymerization solution. To that end, water was added at increasing 
concentrations in the polymerization solution until uniform film growth was observed.  If 
excessive water was present, films showed visible bubbles due to Mg corrosion during the 
polymerization.  
 The film drying protocol following polymerization was also optimized. 
PEDOT/GO films after polymerization were in a solvated form and showed a significant volume 
decrease during drying.  Drying at ambient temperatures resulted in rapid evaporation of the 
ethanol and prompt drying of the film. These quickly dried films displayed non-uniform 
thicknesses, visually observed as darker patches, as well as bubbles and cracks in the coating.  
To slow the drying, samples were placed at -20oC for two days followed by storage at 4oC for 
one day.  Following this process, films presented uniform color and no appearance of cracks or 
bubbles. Polymerization at optimized conditions resulted in uniform films with a rough surface 
texture (Fig. 2-4A and 2-5 A&C) compared to Mg (Fig. 2-4B and 2-5B).  This rough surface 
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texture resembles that shown previously by our lab and is a result of the GO sheets protruding 
from the surface of the polymer film[103].  Following the above drying protocol the thickness of 
the coating was quantified using SEM and comparing coated and uncoated Mg ribbon 
thicknesses.  It was determined that the PEDOT/GO coating procedure resulted in a 50nm thick 
coating once dried. 
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Figure 2-4: Macroscopic morphology. (A) PEDOT/GO coated Mg before corrosion (B) Mg sample 
before corrosion (C) PEDOT/GO sample post corrosion (D) Mg sample post corrosion 
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2.4.2 SEM and EDX analysis 
Images of un-corroded samples as well as samples corroded in PBS for 22 days were analyzed 
under SEM (Figs. 2-4 and 2-5). Pre corrosion, Mg samples exhibited a rough surface 
morphology presumably due to oxides and hydroxides formed upon exposure to ambient air.  
The PEDOT/GO coated samples show uniform coverage with a rough surface morphology 
resulting from the GO sheets being exposed at the surface[103]. Following corrosion, 
PEDOT/GO coated samples display cracks in the coating as well as areas where the coating 
delaminated.  PEDOT/GO samples showed coating delamination of varying degrees with one 
sample having a large portion of the coating removed and two remaining largely intact 
throughout the 22 day corrosion.  It is likely that the cracking of the film visualized under SEM 
was exacerbated by the SEM sample drying preparation.  Of interest is the morphology of the 
underlying Mg after corrosion. Images revealed cracked plate like morphology of exposed Mg 
around the PEDOT/GO coated areas (Fig. 2-5D). Uncoated Mg samples, however, 
predominantly displayed an amorphous morphology with only some areas of cracked plate like 
morphology on the edge (Fig. 2-5E).  There is also evidence that the cracked plate like 
morphology was present underneath the PEDOT/GO coating as seen through the cracks in the 
coating (Fig. 2-5F).  EDX analysis was conducted on both the cracked and amorphous 
morphologies and it was found that the scale morphology displayed higher percentage of oxygen 
and phosphorus than the amorphous areas (Fig. 2-6). This suggests that the uncoated samples 
were predominantly coated with a Mg(OH)2 while the PEDOT/GO coated samples displayed a 
Mg3(PO4)2 in the areas where the PEDOT/GO coating began to fail. 
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Figure 2-5: Micro morphology. (A) PEDOT/GO coated sample before corrosion.  A rough surface 
morphology can be seen indicative of GO sheets exposed at the surface. (B) Untreated Mg surface. (C) High 
magnification image of PEDOT/GO coating to better illustrate surface roughness.  (D) Delaminated area on 
PEDOT/GO coated sample after corrosion showing the cracked scale like morphology taking up the entire 
delaminated area. (E) Uncoated Mg after corrosion. White arrow indicates similar cracked morphology 
predominantly present on the edges of the sample while the majority of the sample displayed a more 
amorphous morphology indicated by the black arrow. (F) Image of a crack in the PEDOT/GO film after 
corrosion where the cracked scale like morphology can also be seen as indicated by the white arrow. 
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Figure 2-6: EDX post corrosion. (A) EDX of the dominant amorphous morphology on uncoated Mg 
after corrosion. (B) Elemental analysis of the scale morphology present on the edge of uncoated Mg. (C) 
Elemental analysis of scale morphology on PEDOT/GO coated Mg where the coating had delaminated. 
2.4.3 Corrosion Characterization 
Mg corrosion in aqueous solution, with or without the PEDOT/GO coating, involves several 
anodic and cathodic reactions as shown in equations 1-4 below.  The assessments of corrosion 
often target different reaction products.  Multiple methods to characterize corrosion have been 
reported in literature [11, 173, 178, 192, 193]. To obtain a comprehensive understanding, we 
utilized multiple metrics to analyze the corrosion of PEDOT/GO coated and uncoated samples. 
2H2O + 2e-  H2 + 2OH- (cathodic)       (1) 
Mg  Mg2+ + 2e- (anodic)        (2) 
Mg +2H2O  Mg2+ + OH- + H2 (complete reaction)     (3) 
Mg2+ + 2OH-  Mg(OH)2        (4)   
2PEDOT+/GO- + 2e-   2PEDOTneutral/GO- (polymer film reduction)  (5) 
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2.4.3.1 Tafel Scan 
Potentiodynamic Tafel scans indicate the balance of the cathodic and anodic half reactions. 
Representative Tafel scans for coated and uncoated Mg samples can be seen in Fig. 2-7. The 
PEDOT/GO coated Mg showed a positive shift in the corrosion potential (the point of minimal 
current).  This shift is indicative of a decrease in the sample’s tendency for corrosion.  
Additionally, the PEDOT/GO coating decreased the corrosion current, the current where anodic 
and cathodic half reactions are in equilibrium as determined by the intersection of lines 
extrapolated from the linear portions of the cathodic and anodic arms of the scan.  This too is 




Figure 2-7: Tafel scan. Representative curves for uncoated Mg and PEDOT/GO coated Mg.  It can be 
seen that the corrosion potential for the coated sample is more positive than uncoated and that the corrosion 
current is slightly lower. 
2.4.3.2 Magnesium ion analysis 
Tafel scan is a one-time analysis method that damages the sample and affects further readings.  
For long-term quantification of corrosion, Mg ion concentrations in the corrosion solution were 
analyzed using Magnesium Liquicolor assay.  The reaction of untreated Mg in solution can be 
seen in equation 3.  Oxidation of Mg (equation 2) is balanced by the reduction of water and 
formation of hydrogen bubbles (equation 1).  Mg2+ may then react with anions at the surface, 
most commonly OH-, to form an additional hydroxide layer that is only somewhat corrosion 
protective (equation 4).  Mg ion concentration values, summed over days, can be seen in Fig. 2-
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8.  PEDOT/GO coated Mg had significantly less Mg ions in the corrosion media than untreated 
Mg for all measurements.  PEDOT/GO coatings showed a 37.7±4.3% decrease in the daily 
release of Mg ion in the corrosion media.  Rates of Mg ion release over the first 7 days were 30% 
lower for PEDOT/GO coated samples.  The increase in error of the PEDOT/GO coatings is a 
result of the coating delamination occurring at slightly different rates.   
 
 
Figure 2-8:  Mg ion concentration. Summed Mg ion concentration in the corrosion solution 
quantified daily using xylidyl blue assay. (all p<0.05)  
2.4.3.3 pH analysis 
In addition to Mg ion quantification, pH of the corrosion solution was tested daily. Mg corrosion 
involves the reduction of water as the cathodic partial reaction (equation 1)[11, 193].  This 
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produces hydroxyl anions and consequently an increase in pH.  Summed OH- present in the 
corrosion solution can be seen in Fig. 2-9.  Uncoated samples displayed a significantly greater 
amount of OH- in the corrosion solution than the PEDOT/GO coated samples.  This reduction in 
OH- production is the result of the overall decrease in corrosion rate.  Additionally, the reduction 
of the PEDOT backbone (equation 5) replacing the water reduction partial reaction (equation 1) 
will affect this metric.  Coated samples resulted in a 43% decrease in the rate of OH- production 
and showed a 46±2% decrease in the daily OH- generated. 
 
 
Figure 2-9: Hydroxide in the corrosion solution. Summed OH- concentration in the corrosion 
solution calculated daily from pH measurements. (all p<0.05) 
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2.4.3.4 Electrochemical tests 
The long term corrosion samples were also subject to daily electrochemical tests.  These tests 
include OCP and EIS measurement and were performed immediately after transferring the 
corroding samples to fresh PBS.  These tests were designed to have a negligible effect on the 
corrosion reaction and could be repeated each day without affecting the samples. 
2.4.3.5 OCP 
OCP is a real time representation of corrosion potential displayed in the Tafel scans.  It can be 
seen in Fig. 2-10 that the OCP values for the PEDOT/GO coated samples were more positive 
than the uncoated samples at all time points, which is indicative of lower corrosion rates. There 
was a sharp negative shift in corrosion potential in the first 24 hours for the PEDOT/GO coated 
samples.  This drop is likely due to film cracking during the first 24 hours leading to a 
compromised barrier function.  However, despite the drop, the OCP of the coated sample is still 
more positive than the uncoated and remained more positive throughout the 22-day experiment.  
Small isolated stagnant bubbles were visible after 24 hours on some of the PEDOT/GO coated 
samples.  Following the film damage, the PEDOT/GO facilitated the formation of the Mg3(PO4)2 
layer, while on the untreated samples a less stable Mg(OH)2 layer was formed.  The barrier layer 
protection provided by the PEDOT/GO, as well as the formation of the magnesium phosphate 
resulted in the higher OCP when compared to the uncoated samples.  
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Figure 2-10: Open circuit potential  Average OCP recorded daily for PEDOT/GO coated Mg and 
uncoated Mg. (* p<0.05) 
2.4.3.6 EIS 
Immediately after OCP readings, EIS was recorded.  EIS and equivalent circuit modeling can 
provide better understanding of the sample/electrolyte interface and the effect of the coating on 
corrosion.  Nyquist plots for uncoated and coated samples over the course of the experiment can 
be seen in Fig 2-11. The radius of the Nyquist plot is attributed to the corrosion resistance with 
larger radii indicating higher corrosion resistance[194, 195].  Here the uncoated sample shows an 
initial increase in the radius of the Nyquist arc followed by a decrease towards the end of the 
experiment.  This is likely due to the initial formation of a Mg(OH)2 (equation 4) layer on the 
uncoated samples after immersion in the corrosion media.  This hydroxide layer is known to be 
unstable in chloride solutions [11] and the decrease in protection is likely due to the attack of the 
Cl- from the corrosion solution facilitating corrosion.  Conversely, the PEDOT/GO coatings 
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showed an increase in the radius of the Nyquist arc over initial days and the protection was 
maintained for the duration of the experiment.  This is due to the barrier layer properties as well 
as the formation and continued maintenance of the Mg3(PO4)2 corrosion protection layer. 
 
 
Figure 2-11: EIS. Representative Nyquist plots from EIS data taken on the same coated and 
uncoated samples at days 2, 10, and 22. 
2.4.3.7 Equivalent circuit analysis 
The equivalent circuit used to describe coated and uncoated samples can be seen in Fig 2-12.  
This is a common circuit used to describe corroding samples with coatings [90, 196-200], and 
has particularly been applied to magnesium with either an inherent oxide/hydroxide layer or 
other topically applied coatings[56, 201-203].  This circuit consists of solution resistance (Rs), 
coating capacitance (CPEc), resistance of ion conduction through the coating (Rc), double layer 
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capacitance (CPEdl), and polarization resistance (Rp). Both CPEc and CPEdl are constant phase 
elements, non-ideal capacitors, where an n=1 is ideal capacitor behavior[204]. 
 Equivalent circuit analysis employed constant solution resistance due to constant PBS 
concentration and low resistance of the solution. Values Rp and CPEdl describe the 
electrochemical reactions occurring at the Mg interface, where Rp is the faradaic charge transfer 
reaction of Mg corrosion. Rp is therefore the sample’s corrosion resistance. As can be seen in 
Fig. 2-12 B, PEDOT/GO coated samples had a significantly higher Rp than uncoated samples 
indicating resistance to faradic corrosion.  Double layer capacitance (CPEdl) is another 
component representing the metal/solution interface. Uncoated samples exhibited increased 
CPEdl indicating a greater surface area of metal in contact with the corrosion solution.  This is 
likely due to the increased pitting corrosion and the more amorphous morphology of the 
corrosion products on the surface of the uncoated samples. Circuit components Rc and CPEc 
represent properties of the coatings on the surface of the Mg.  For PEDOT/GO, Rc and CPEc are 
affected by both the PEDOT/GO coating and the passive phosphate layer.  For the uncoated 
samples, Rc and CPEc are affected by only oxide and hydroxide layers formed on the surface.  
There is very little difference between the coated and uncoated samples for the (Rc) indicating 
that the Mg(OH)2 coating on the uncoated samples had similar ability to prevent the solution 
from reaching the underlying Mg as did the passive layer in combination with the PEDOT/GO 
coating.  This is likely due to the amorphous morphology of the Mg(OH)2, the visible damage to 
the conducting polymer during corrosion, and the cracks of the phosphate layer visualized under 
SEM.  Additionally, while the magnesium hydroxide may have prevented corrosion media 
infiltration, it is continually being eroded away by the chloride ions in the corrosion media.   
Coating capacitance (CPEc) was greater for coated samples during initial time points which is 
 46 
attributed to the increase in surface area facilitated by the conducting polymer and its nano- 
topography [125].  Excessive water infiltration of the oxide/hydroxide film on the uncoated 
samples likely caused the increase in capacitance at later time points. CPEdl and CPEc are 
constant phase elements that are mathematical expressions to indicate non-ideal capacitor 
behavior.  Here where n value indicates how closely they behave to an ideal capacitor with n=1 
representing an ideal capacitor with a phase angle of 90o and n=0.5 representing a capacitor with 
a phase angle of 45o, n values displayed in Fig. 2-12 F &G.  This data, especially the continually 
significant increase in Rp of the coated samples, serves as further evidence that the PEDOT/GO 
coating improves Mg corrosion resistance. 
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Figure 2-12: Equivalent Circuit Modeling. (A) Equivalent circuit used for subsequent modeling. (B) 
Polarization resistance [Rp] representing the samples resistance to faradaic charge transfer through 
corrosion. (all p<0.05) (C) Pore resistance [Rc] indicative of the resistance of ion travel through the coatings 
on Mg. (*p<0.05) (D) Double layer capacitance [CPEdl] indicative of the charge on the surface of the Mg. 
(*p<0.05) (E) Coating capacitance [CPEc] indicative of charge on surface of any coating on the samples. 
(*p<0.05) (F & G) Idealness of the constant phase element representing double layer capacitance and coating 
capacitance respectively indicating how closely samples behaved to acting like a perfect capacitor. (*p<0.05) 
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2.4.4 Hydrogen evolution 
Similar to Mg ion concentration and pH, hydrogen evolution measurements monitor a byproduct 
of the Mg corrosion reactions. Cumulative H2 evolution from coated and uncoated samples can 
be seen in Fig. 2-13. Coated samples released less hydrogen than the uncoated samples, 
indicating that the coating is preventing corrosion or bypassing the water reduction reaction by 
PEDOT/GO reduction. As noted above the PEDOT/GO coated samples did display small 
isolated bubbles after about 24 hours of immersion, however those bubbles were stagnant and 





Figure 2-13: Hydrogen evolution.  Cumulative hydrogen evolution of coated and uncoated samples 
corroded in PBS. (all p<0.05) 
2.4.5 Cytotoxicity 
Assessment of corrosion byproduct cytotoxicity was conducted with the LDH assay as well as 
Live/dead staining.  As can be seen in Fig. 2-14, both methods show a significant decrease in 
toxicity for the PEDOT/GO coated Mg corrosion media. 
2.4.5.1 LDH 
Initially, cytotoxicity was tested utilizing an LDH assay where the amount of LDH released by 
damaged cells into the media was quantified after exposure to 24-hour corrosion media.  Results 
in Fig. 2-14A show a significant decrease in sample toxicity after coating.  The PEDOT/GO 
coating significantly improved biocompatibility for both 100% and 50% corrosion media 
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samples.  100% corrosion media exposure showed a 40% decrease in toxicity as a result of 
PEDOT/GO coating.  Cytotoxicity of cells exposed to 50% corrosion media showed an 86% 
decrease in toxicity.  10% corrosion solutions showed a trend of the coated samples being less 
toxic, though not significant.  Presumably, at such high dilution, the differences between the 
coated and uncoated samples are negated. 
2.4.5.2 Live/Dead assay 
To assess longer term corrosion media toxicity, analysis was also conducted where samples were 
allowed to corrode for 72 hours.  Coated samples showed good stability during the corrosion 
period with no visible delamination. As can be seen in Fig. 2-14 B, corrosion media of coated 
samples showed a 25% reduction in cytotoxicity at 50% corrosion media dilution.  With the 10% 
corrosion media, there is a slight trend towards coated samples being less toxic, though not 
statistically significant. Large amounts of death were observed for both coated and uncoated 
samples at 100% media concentration to the point where quantification could not be completed. 
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Figure 2-14: Cytotoxicity.  (A) Cytotoxicity assessed through LDH quantification of neurons exposed 
for 24hours to corrosion media that had coated or uncoated samples corroded in it for 24 hours. (B) Percent 
cytotoxicity of neurons after 24 hour exposure to media that had coated and uncoated samples corroded in it 
for 3 days assessed through live dead staining. (* p<0.05) 
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2.5 DISCUSSION 
Conducting polymers have demonstrated varying degrees of success as corrosion control 
coatings on metals other than Mg with potential mechanisms of protection varying widely [184, 
205-213].  There has however been little investigation into the corrosion protection of CP on 
Mg[186, 187].  Here we show that PEDOT/GO can be electropolymerized on Mg, and the 
coating reduced corrosion rates and hydrogen evolution, as well as improved cytocompatibility. 
Protocols for analyzing Mg corrosion are varied and can result in different interpretations 
of the corrosion rate[173].  To address these issues, multiple corrosion assessment techniques 
were conducted on the same set of samples.  Damaging electrochemical tafel scans initially 
showed both a decrease in corrosion current as well as positive shift in corrosion potential 
indicative of greater resistance to corrosion.  This test is a representation of early corrosion 
protection provided by the PEDOT/GO film and is likely largely due to the barrier properties of 
the coating.  Non-damaging techniques were utilized for long term corrosion measurement.  Both 
Mg ion and pH tests (Figs. 2-8 & 9) show a decreased corrosion rate for PEDOT/GO coated 
samples. Here, Mg ion assay assesses the presence of Mg ions in the corrosion solution resulting 
from the anodic reaction (equation 2) while pH represents products of the cathodic reaction 
(equation 1).  Both of these metrics relate to the overall corrosion of the Mg. 
 Comparisons of the electrochemical data similarly indicated that the PEDOT/GO 
coating improved corrosion resistance.  OCP data of PEDOT/GO coated samples displayed a 
positive corrosion potential at initial time points followed by a drop and recovery indicating the 
formation of the magnesium phosphate.  Nyquist plots, as well as equivalent circuit analysis, also 
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revealed that the PEDOT/GO coatings were more resistant to corrosion displaying greater 
polarization resistance for the duration of the experiment. 
SEM analysis of the coated and uncoated samples post corrosion revealed distinctly 
different surface morphology. Uncoated samples were largely covered in a layer of an 
amorphous morphology with a composition typical of Mg(OH)2. All PEDOT/GO coated samples 
had regions where the coating had begun to fail and the underlying Mg was exposed.  These 
exposed regions showed a distinct scale morphology. EDX revealed increased phosphorous and 
oxygen content compared to the amorphous region. These data indicate that where the 
PEDOT/GO coating began fail, a unique corrosion byproduct Mg3(PO4)2 was formed on the 
surface of the PEDOT/GO coated samples.   
The PEDOT/GO coating facilitated this phosphate formation by utilizing its positively 
charged backbone as an alternate cathodic reduction reaction in the corrosion reaction.  During 
corrosion on uncoated samples, Mg ions from the anodic half reaction and OH- ions from the 
cathodic half reaction react with one another to form Mg(OH)2 on the surface (equation 4)[11, 
193].  This mechanism is displayed in Fig. 2-15 A.  This Mg(OH)2 film is generally porous, non-
uniform, and chemically unstable making it a poor corrosion protection layer[214, 215]. By, 
replacing the traditional cathodic reaction (equation 1) with PEDOT/GO reduction, the positive 
backbone of the PEDOT is reduced to neutral and the generation of OH- by equation 2 is 
diminished[216]. As a result, there is an increase probability that the Mg2+ will react with the 
phosphate in the solution.  This mechanism is displayed in Fig. 2-15B. Previous reports have 
noted that the conducting polymer coatings facilitated the growth of a passive oxide layer on 
other metals[90, 217-221] in a manner similar to that proposed here.  Additionally, reactions 
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displayed in Fig. 2-15B are similar to those proposed for certain anodized coatings containing 
phosphate[222]. 
These magnesium phosphate coatings provide increased corrosion resistance in that they 
are a denser and less soluble protection layer[223-228].  Phosphate conversion coatings are 
common techniques for improving corrosion resistance, and phosphate-based coatings on Mg 
have shown promise as corrosion prevention techniques [223, 224, 228-230].  Corrosion of Mg 
alloys in solutions containing phosphate at concentrations mimicking biologic fluids have 
resulted in the precipitation of a semi corrosion-protective phosphate layer[231, 232].  Phosphate 
containing layers have also been deposited on steel and Mg alloys by immersion into magnesium 
phosphate baths[222, 225, 226]. Both pure Mg and Mg alloys coated with these phosphate 
coatings demonstrated improved corrosion protection as well as a deposition of a phosphate 
protective coating in areas were the phosphate coating was damaged[222].  Phosphate coatings 
on Mg alloys have also been conducted through plasma electrolytic oxidation (PEO)[233].  
Similar to the phosphate coatings deposited from solution, these PEO deposited coatings 
improved corrosion resistance and a re-passivation of damaged areas through the formation of a 
phosphate layer was observed. Both the solution deposited[222] and PEO deposited[233] 
phosphate protection layers displayed a surface with cracked morphology, similar to that 
observed here, where the coating had been damaged and a new phosphate layer formed.  The 
facilitation of this phosphate intermediate in the area where the PEDOT/GO coating became 
damaged provides further corrosion protection even as the PEDOT/GO coating begins to fail.   
The formation and maintenance of the phosphate layer is reliant on the polymer’s ability 
to be reduced.  As more Mg is exposed, there is a greater demand on the coating to generate the 
protective layer. Consequently, the polymer is further reduced.  To increase the lifetime of 
 55 
protection, PEDOT/GO films have the ability to be re-oxidized by dissolved oxygen in the 
solution, facilitating maintenance of the PEDOT protection[221].  It is however likely that this 
re-oxidation of the polymer backbone cannot maintain the same rate as the reduction provided by 
the Mg corrosion.  Once the film has been completely reduced, it will act as a passive barrier 
layer in the areas where it is still adhered to the Mg. 
For PEDOT/GO coated samples, early values for Mg2+ and OH- concentrations indicate 
an initial low production of corrosion byproducts compared to the uncoated samples which had a 
high concentration of corrosion byproducts in the solution throughout the 23 days tested.  This is 
likely due to initial passive barrier layer corrosion protection provided by the PEDOT/GO 
followed by reactions between the Mg, PEDOT/GO, and PBS that make the coating even more 
protective.  Normally, following reduction of the polymer backbone, small negatively charged 
dopants are no longer held in the film and have the ability to diffuse out.  However, with large 
graphene oxide sheets acting as the dopant in the PEDOT/GO film, the GO sheets remain 
trapped in the PEDOT matrix following reduction[102].  This causes the film to have a net 
negative charge which can further improve corrosion resistance by preventing aggressive 
negative ions like Cl- from reaching the surface[114, 234].   
 Because of the allure of a degradable magnesium nerve guide implants[235, 236], 
in vitro primary neuronal culture was used as test bed to assess the effect of the PEDOT/GO 
coating on cytotoxicity of Mg implants. Reduced toxicity was observed by the PEDOT/GO 
coating in two different assays.   Our lab has previously shown that PEDOT/GO film itself is 
exceptionally biocompatible and promotes the attachment and neurite extension of primary 
neurons[102, 103, 237].  The lowered toxicity afforded by the PEDOT/GO coating is likely due 
to two factors.  Firstly, PEDOT/GO coatings decrease Mg ion concentration in solution, which at 
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elevated levels, has been shown to be toxic to neurons[238, 239].  Secondly, PEDOT/GO 
coatings maintained a more neutral pH due to the lack of OH- production as the reduction of the 
polymer takes the place of water reduction[114].  Additionally, a potential benefit not 
demonstrated by corrosion media exposure tests is the prevention of hydrogen production.  
Hydrogen bubble formed during corrosion causes tissue dislocation from the implant and results 
in implant failure [9, 15, 17].  As discussed previously, the PEDOT/GO coating prevents water 
reduction and consequently decreases the formation of hydrogen bubbles.  This benefit may 
serve to improve in vivo implant biocompatibility in future experiments. 
 This PEDOT/GO coating has demonstrated the ability to slow magnesium corrosion, 
improve biocompatibility, and electrochemically decrease the production of hydrogen gas, all of 
which are important properties for improving the clinical potential of Mg implants.  In addition 
to these benefits, future exploration will involve the release of anti-inflammatory drugs from the 
coating to reduce the host tissue response [102].  Additionally, the GO sheets exposed at the 
surface of the film provide loci for surface functionalization which can allow for improved tissue 
interaction with the implant[103].  The combination of improved corrosion resistance, the ability 
to release drug at the site of corrosion, as well as improve tissue interaction through surface cues 
make this composite material a promising versatile coating for numerous potential applications 
of degradable Mg implants. 
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Figure 2-15: Corrosion Protection Mechanism.  (A) Reactions facilitating the less corrosion 
protective Mg hydroxide formation for the uncoated samples. (B) Reactions occurring on the PEDOT/GO 
coated Mg samples in the area of film damage that lead to the formation of the corrosion protective 
magnesium phosphate layer. 
2.6 CONCLUSION 
Here PEDOT/GO coatings were electropolymerized on Mg ribbon as uniform and adherent 
coatings.  Coated Mg samples showed decreased corrosion rates when evaluated with Mg ion 
concentration and pH of corrosion media, hydrogen evolution, and electrochemical techniques. 
Initially, PEDOT/GO coatings acted as passive barrier layers.  Following diffusion of media 
through the film, the coating facilitated continued corrosion resistance through an increase in the 
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negative charge on the film and the formation of a magnesium phosphate layer. In vitro neuron 
cytotoxicity experiments demonstrated that the PEDOT/GO coating improves the 
biocompatibility of the Mg samples. This research provides new insight into the potential for 
conducting polymers to act as effective corrosion control coatings on magnesium biomedical 
implants through multiple mechanisms. Such coatings will be highly desired for various Mg 





3.0  SELF-POWERED THERAPUTIC RELEASE FROM CONDUCTING POLYMER 
FILMS ON MAGNESIUM 
3.1 ABSTRACT 
Magnesium’s ability to degrade away completely in vivo makes it an appealing material for 
medical applications.  However, rapid corrosion, generation of hydrogen gas, and a lack of 
ability to add additional biomolecular cues have limited the clinical use of Mg.  Here we report 
on the polymerization of a PEDOT/GO film on Mg with the addition of anti-inflammatory 
dexamethasone (Dex).  The ability of this film to protect from corrosion and decrease hydrogen 
evolution is investigated.  PEDOT/GO/Dex coatings on Mg improved corrosion resistance when 
evaluated through EIS, Tafel scans, and Hydrogen evolution.  Additionally, the release of Dex 
from the film is explored both through application of external stimulation as well as through 
using the current generated during Mg corrosion.  External electrical stimulation increased the 
rate of drug release.  Corrosion generated current was also significant enough to drive release 
from the film and the amount of exposed Mg altered drug release rates.  Bioactivity of the 
released Dex was confirmed though cell culture of released Dex with microglia stimulated with 
LPS. Here, released Dex was able to suppress the activation of the microglia.  Not only does this 
PEDOT/GO/Dex coating have the ability to subdue Mg corrosion, it also can act as a smart 
releasing coating that delivers Dex at the site of corrosion to combat detrimental effects of 
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corrosion byproducts on local tissue.  This self-powered smart coating could help combat the 
current issues preventing the use of Mg as medical implants.  
3.2 INTRODUCTION 
Implantable drug delivery devices have been drawing additional attention in recent years due to 
their benefits over oral and injectable therapeutics.  By implanting a device that releases 
controlled amounts of drugs to the tissue local to the device, clinicians have the ability to deliver 
higher local dosages, minimize potential side effects, decrease total drug required to treat the 
patient, and protect drugs that may be too unstable to deliver with normal delivery methods[130, 
240].  In addition, implantable devices may contain smart release systems as well as sensors and 
logic components to control drug delivery timing without the need for clinician supervision[241-
243].  Implantable drug delivery devices have a wide variety of potential applications from 
cancer treatments to ingestible devices that deliver drug to the complex geometry of the small 
intestine[243-246].  These devices have initially taken advantage of microelectromechanical 
systems (MEMS) using silicon technology developed for the electronics industry[247-249].  
However, these silicon based devices suffer from poor biocompatibility and require removal 
once the therapeutic reservoir is exhausted, or no longer needed [250, 251].    
To address these issues, biodegradable materials are being investigated as drug delivery 
platforms.  Conventional drug releasing systems largely include degradable polymers that serve 
as a reservoir for the drug of interest whereby the drug is released as the polymer degrades [252-
255].  These systems however are not smart and cannot be precisely turned on and off according 
to the demand. There has recently been a push towards using degradable materials to form 
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MEMS devices that would allow the same sensors and logic as current devices but eliminate the 
need for removal surgery and minimize the biocompatibility issues from chronic presence[256-
259]. In addition to the electronics for controlling the implantable drug delivery devices, safe 
power sources are needed to drive active drug release mechanisms[260, 261].  To that end a 
variety of power storage solutions that are more biologically friendly than current Lithium ion 
batteries are being explored.  These include new sodium ion batteries[262, 263] as well as 
batteries that harness biomolecules to derive power[264]. 
Magnesium (Mg) is a promising material for use in implantable devices largely due to its 
safe biodegradation [15, 17, 173, 177, 192].  Additionally, Mg has a high strength to weight 
ratio, excellent electrical properties, and is compatible with some traditional MEMS fabrication 
processes [36, 39, 175, 265, 266].  As the fourth most common cation in the body, Mg takes part 
in a variety of biologic processes including ATP energy generation and DNA synthesis, and has 
been shown to promote bone growth and nerve regeneration[176, 179-181, 266].  Corrosion of a 
Mg implant results in local release of Mg ions, OH-, and hydrogen which can diffuse away 
provided the corrosion rate is slow[9].  This leads Mg to be a promising structural material for 
degradable implants as well as useful for developing degradable electronic systems.  
Furthermore, Mg is a potential anode for galvanically coupled power sources [267-269].  Here 
the electrons generated during corrosion can be utilized to power sensors and drug delivery 
devices.  This combination of properties makes Mg a promising material for use in degradable 
self-powered drug delivery devices.   
 Biodegradable polymers that release therapeutics as they degrade have been 
deposited on the Mg surface to achieve the goal of a self-contained biodegradable drug releasing 
platform [80-82, 270-273].  This technique provides some control of drug release based on 
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polymer degradation rates but these coatings only act as a passive barrier layer preventing 
corrosion.  Once the degradable polymer layer has been hydrolyzed away, Mg corrosion will 
proceed unhindered.  While the eventual degradation of Mg is desired, previous reports have 
shown Mg is prone to rapid corrosion and loss of mechanical properties in addition to the 
excessive formation of hydrogen bubbles[15, 18, 42, 175, 182, 274].  Therefore, to address 
corrosion and maintain drug releasing properties, additional coatings and alloys are utilized in 
conjunction with the degradable polymer coatings.  To better improve Mg’s future potential, it 
would be ideal if a single coating could both protect Mg from corrosion as well as deliver 
therapeutics. 
 Conducting polymers (CP) offer a unique ability to accomplish both of these 
goals.  CPs have been shown to be corrosion protective on a variety of different metals[89, 90, 
114]. Mechanisms proposed for this protection however vary greatly depending on polymer, 
dopant, and sample pretreatment[184, 205-209, 212].  Proposed mechanisms for corrosion 
protection via conducting polymers include; a barrier layer, ennobling, anodic protection, 
formation of a modified CP metal interface, facilitation of a protective oxide, shifting of the 
electrochemical interface[89, 90, 114].  Additionally, CPs with corrosion inhibiting dopants have 
been used to decrease corrosion[114, 185, 207, 208].  Here, in the location where the CP begins 
to fail, the current generated by metal corrosion reduces the polymer and facilitates the release of 
dopant local to the site of film damage.  When released, this dopant reacts with the corroding 
metal to form passive corrosion protecting layers.  This corrosion triggered release of dopants 
from CPs has currently had little research in the use of bioactive dopants instead of corrosion 
protecting dopants.   
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 Another mechanism of corrosion protection by CPs was reported in Chapter 2 where a 
CP film poly 3,4-ethylenedioxythiophene (PEDOT) doped with GO minimized corrosion of Mg 
through electrochemical interactions during corrosion.  Here the conducting polymer is reduced 
as the underlying or exposed areas of metal are oxidized.  This electrochemical interaction 
between the CP and the metal facilitates a corrosion protective layer to prevent further corrosion 
of the metal. 
 In addition to being used for corrosion protection, CP drug release through redox 
reactions has been well documented[98, 100, 101, 110, 133].  During polymerization, the 
polymer backbone is oxidized requiring negative dopants to provide charge balance.  Following 
polymerization, reduction of the CP removes the positive charge on the backbone releasing the 
negative dopants.  This electrically controlled release provides good temporal control of the drug 
release rate.  Additionally, there are multiple ways in which CP dopant composites can be altered 
to adjust the release rate[100, 101, 113].  One mechanism previously reported in our lab is 
through the addition of graphene oxide (GO) sheets[102].   These sheets allow for altering both 
the amount of drug loaded into the film as well as the release rate of the drugs. Here, drug 
loading is accomplished via the π-π stacking of the drug molecule on the GO.  In the polymer 
solution, the drug which has aromatic rings, stacks on the GO and is carried into the polymer as 
the negative charge on the GO facilitates GO doping into the CP film.  The amount of drug that 
is carried into the polymer is dependent on the size of the GO sheets.  Additionally, CPs with 
large immobile dopants, like GO sheets, can be used to incorporate positively charged 
therapeutics following polymerization[275-277] as well as carry in uncharged molecules.   
Similar to CPs, GO has shown both corrosion control abilities as well as drug releasing 
properties.  GO is an atomically thin layer of carbon functionalized with hydroxyl, epoxide, and 
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carboxylic acid groups[140].  GO alone has been used as a controlled drug release system largely 
for aromatic containing components[158, 278-281].  Here the drugs with aromatic rings in their 
structure are loaded on to the GO via π-π stacking in addition to hydrogen bonding.  Release is 
typically accomplished via pH changes, however other methods including use of degradable 
ester bonds, degradable disulfide bonds, and ultrasound stimulation have been used to release 
drug from GO[156].  Electrical stimulation has also been used to enhance drug release from 
GO[278]. In addition to aromatic drugs, GO has been used for non-aromatic drug release[282], 
gene delivery[156], and aptamer delivery[145]. 
Graphene and GO have also been used as corrosion protection layers.  Graphene sheets 
largely are used for their barrier properties and can provide corrosion protection both if they are 
grown on the substrate and if they are transferred to a new substrate[151-153].  The additional 
negative charges on the GO can further inhibit the corrosion by preventing aggressive negative 
ions from reaching the surface[154, 155].  GO coatings have even been used as barrier layers on 
Mg alloys following PEO treatment to further improve corrosion resistance[283]. 
A composite film of CP and GO may also be beneficial for corrosion protection.  Doping 
the CP with GO traps the GO within the polymer network.  Reduction of the CP/GO film then 
creates a net negative charge due to the GO’s inability to diffuse away[114].  Consequently 
positive components from the solution are incorporated into the film.  This process can be 
utilized to entrap and release neutral and positive dopants[112, 276].  These two cases show that 
the addition of GO to the CP helps diversify the films drug releasing properties making it 
applicable for different application needs. 
 Here we report the use of a CP film of poly 3,4-ethylenedioxythiophene (PEDOT) doped 
with GO containing Dex on Mg.  Dex is a general steroidal anti-inflammatory that minimizes 
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inflammation around the implant site improving implant outcomes and has been shown to be 
effective in a variety of tissues[284-287].  We show that the PEDOT/GO/Dex film can control 
Mg corrosion, has a tunable drug release rate, and that the drug remains bioactive. Furthermore, 
previously reported electrically controlled release systems require a power source and wiring to 
the power the release, which may not be readily available. We show that drug release can be 
driven by the Mg corrosion current, consequently eliminating the need for external power. 
3.3 MATERIALS AND METHODS 
3.3.1 Materials 
Single layer graphene oxide sheets were purchased from Cheap Tubes (Cambridgeport, VT).  
200 proof ethanol was purchased from Decon Labs Inc. (King of Prussia, PA).  Magnesium 
ribbon ≥99.5% (3 mm wide x 0.2 mm thick), 3,4-ethylenedioxythiphene (EDOT) monomer, and 
dexamethasone were purchased from Sigma-Aldrich.  PBS 10x concentrate (136 mM NaCl, 2.7 
mM Potassium chloride, 10 mM Phosphate Buffer) was purchased from EMD Millipore 
(Billerica, MA) and diluted using de-ionized water from a Millipore Milli-Q system. 
3.3.2 PEDOT/GO/DEX film polymerization 
Composite films of PEDOT and GO, as well as PEDOT/GO/Dex were polymerized on Mg (20 
mm x 3 mm x 0.2 mm, Sigma) and gold (20 mm x 3 mm x 0.1 mm, Ted Pella) strips.  Prior to 
polymerization, samples were sonicated in ethanol briefly then dabbed dry.  The polymerization 
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solution was created in two stages.  Firstly, 10 mg/ml single layer GO (Cheap Tubes, 
Cambridgeport, VT) with and without 3.3 mg/ml Dex were added to 200 proof ethanol and 
sonicated for 30min. Sonication facilitated loading of the Dex on the GO for those samples with 
Dex.  35 µl and 20 µl of water and EDOT monomer respectively were then added per ml of the 
GO/±Dex/ethanol solution and triturated to make the final polymerization solution.   
 Polymerization was conducted in this solution using a Gamry 
potentiostat/femtostat on the Gamry Framework software.  A two-electrode system was used 
with the sample to be coated as the working electrode and a gold counter/reference electrode.  
Polymerization was conducted at 0.6 V vs. Au until a total charge of 10 mC with samples 
immersed in the solution 9 mm.  Following polymerization, samples were dipped in ethanol and 
stored at -20oC for 48 hours followed by 2oC for 24 hr.  Samples were then stored at room 
temperature until release. 
3.3.3 SEM 
SEM analysis was conducted using a Jeol JSM 6330F SEM using an accelerating voltage of 3 
kV.  Samples were analyzed following above drying procedures in addition to an overnight 
storage in a vacuum desiccator.  Coating integrity and surface morphology of coated and 
uncoated samples were analyzed. 
3.3.4 Impedance spectroscopy 
A three-electrode system was used to measure EIS with an Ag/AgCl reference, platinum counter, 
and Mg working electrode.  PEDOT/GO and PEDOT/GO/Dex as well as uncoated Mg ribbon 
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samples were immersed 5 mm into PBS for the scan.  This ensured only the coated portion of the 
sample was exposed to the PBS.  Samples were allowed to sit in PBS for 5 minutes prior to 
running EIS analysis.  Following the 5 minutes, OCP was recorded for 20 s or until it reached a 
stability of 0.05 mV/s.  EIS was then taken from 100 kHz to 0.1 Hz with an applied potential of 0 
V vs. OCP and a voltage amplitude of 10 mV.  
3.3.5 Tafel Scan  
Following EIS, using the same electrochemical cell, Tafel scans of the samples were conducted.    
Open circuit potential was recorded for 20 seconds prior to the scan.  The scan was then run from 
-0.25 V to +0.25 V vs. OCP. 
3.3.6 Hydrogen evolution 
PEDOT/GO/Dex coated Mg as well as uncoated Mg samples were mounted in epoxy on glass 
microscope slides so that 5 mm of the sample was exposed.  Samples were then placed in a 2 L 
crystallization dish that was filled with PBS.  2ml plastic pipettes were modified so that the tip 
was closed and the opposite end was flared out.  These pipettes were filled with PBS and placed 
over the corroding samples.  Hydrogen evolved from the samples rose up the pipette and 
collected at the top allowing for quantification of the total evolved hydrogen. 
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3.3.7 Powered release 
Electrochemical release from PEDOT/GO/Dex on Mg was stimulated using the Gamry system 
with a three electrode system using a Pt counter electrode and Ag/AgCl reference electrode in 
3ml PBS.  Samples, immersed in the solution 5 mm, were subject to pulsatile stimulation of -
0.25 V vs. open circuit potential (OCP) for 5s followed by 0 V vs. OCP for 5s.  This stimulus 
was repeated 10 times.  Following stimulation, the absorbance of the release solution was 
analyzed using SpectroMax M5 plate reader at the characteristic absorbance of Dex 242 nm and 
the analyzed solution was returned to the release solution.   This 10 stimulation paradigm 
followed by solution analysis was repeated for a total of 50 simulations.  The number of 
stimulations between solution analyses was then increased. The release solution was analyzed 
after a total of 100, 200, 400, and 600 simulations.  Control samples were placed in PBS and 
measurements were taken at time intervals mimicking the stimulation paradigm but without the 
stimulation. 
3.3.8 Corrosion triggered release 
9 mm of the 20 mm long Mg ribbon samples were coated with PEDOT/GO/Dex.  For passive 
release experiments, ‘long’ Mg samples were left un-altered while ‘short’ Mg samples had 10 
mm of the uncoated portion removed.  Gold samples were all in the ‘long’ form as the amount of 
exposed gold is not expected to affect drug release. Long Mg, short Mg and gold samples were 
completely immersed in 3 ml PBS.  Samples of the release solution were taken at 5 min, 15 min, 
30 min, 1 hr, 2 hr, and 3 hr and absorbance was analyzed with SpectroMax M5 plate reader at the 
wavelength of 242 nm. 
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3.3.9 Bioactivity assessment 
Bioactivity of released dexamethasone was tested using previously reported methods[100].  A 
microglia cell line, Highly Aggressive Proliferating Immortalized (HAPI) cells, was challenged 
with a gram negative bacteria derived lipopolysaccharide (LPS) in combination with Interferon 
gamma. Nitrite content of the culture media was assessed using a Griess reagent kit to determine 
the level of microglial activation.  Dex bioactivity was assessed by the drug’s ability to suppress 
microglia activation and consequently decrease the nitrite production.  Both dexamethasone as 
purchased and as released from the PEDOT/GO/DEX films were compared to assess the 
bioactivity of Dex released from the films. 
 HAPI cells (courtesy of Dr. Xiaoping Hu’s lab, University Pittsburgh) were plated 
at 105 cells/well in a 24 well plate.  After about 24 hours cells reached 80% confluence.  Culture 
media was then removed and replaced with challenging solutions.  These were as follows:  
 
(1) Control: 194 µl PBS and 818 µl DMEM F12  
(2) Released Dex: 182 µl Dex in PBS (10.7 µg/ml) released from PEDOT/GO/Dex 
coatings on Mg, 12 µl PBS, 818 µl DMEM F12  
(3) Control Dex: 182 µl as purchased Dex in PBS (10.7 µg/ml), 12 µl PBS, 818 µl 
DMEM F12  
(3) LPS only stimulation: 182 µl PBS, 10 µl of LPS in PBS (10 µg/ml), 2 µl IFNɤ in PBS 
 (1 µl/ml), and 818 µl DMEM F12  
(4) LPS + released Dex: 182 µl Dex in PBS (10.7 µg/ml) released from PEDOT/GO/Dex 
coatings on Mg, 10 µl of LPS in PBS (10 µg/ml), 2 µl IFNɤ in PBS (1 µl/ml), and 818 µl 
DMEM F12  
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(5) LPS + control Dex: 182 µl as purchased Dex in PBS (10.7 µg/ml), 10 µl of LPS in 
PBS (10 µg/ml), 2 µl IFNɤ in PBS (1 µl/ml), and 818 µl DMEM F12  
 
Cells were incubated in the treatment media for 24 hours at 37oC.  Following 24 hour incubation, 
culture media supernatant was removed and added to Griess reagent kit following instructions.  
Nitrite production was quantified by analyzing this solution with Spectromax M5 
Spectrophotometer at an absorbance wavelength of 540 nm.  Following removal of culture media 
cells were fixed in with 4% paraformaldehyde for 30 min.  Cells were stained with DAPI cell 
nuclei stain for counting.  Fixed and stained HAPI cells were imaged using a Leica DMI 4000 B 
inverted fluorescent microscope and counted in ImageJ using the particle analysis tool. 
3.4 RESULTS 
3.4.1 SEM 
SEM imaging of the PEDOT/GO/Dex samples revealed a uniform coating on the Mg ribbon 
sample (Fig. 3-1 A & B).  Higher magnification images (Fig. 3-1 C) show a rough surface 
morphology resulting from the edges of the GO sheets being exposed at the surface.  This 
morphology is the same as that observed for PEDOT/GO only samples in section 2.4.2 indicating 
that GO sheets have been entrapped in the PEDOT matrix.  Additionally, this morphology 
suggests the carboxylic acid functional groups on the edges of the GO sheets are still available 
for future functionalization.  
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Figure 3-1: PEDOT/GO/Dex Mg morphology.  (A) 20x image of PEDOT/GO/Dex coated Mg. (B) 
100x image of PEDOT/GO/Dex coated Mg. (C) 500x image of PEDOT/GO/Dex coated Mg where the 
morphology provided by the GO sheets can be seen. 
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3.4.2 Impedance Spectroscopy 
Immediately after OCP readings, EIS was recorded to provide additional assessment of corrosion 
protection afforded by the coating.  Nyquist plots for uncoated and coated samples, with and 
without drug, following the 24hr OCP recording can be seen in Fig. 3-2. The radius of the 
Nyquist plot is attributed to the corrosion resistance with larger radii indicating more corrosion 
resistance[194, 195].  PEDOT/GO/Dex films show and increase in the arc radius when compared 
to uncoated Mg (Fig. 3-2 B).  PEDOT/GO only films resulted in a nyquist curves with a 90% 
greater arc radii that PEDOT/GO/Dex films suggesting much better corrosion protection 
performance (Fig. 3-2A). 
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Figure 3-2: PEDOT/GO/Dex on Mg EIS.  (A) Nyquist plots from EIS data collected for PEDOT/GO 
coatings on Mg. (B) Nyquist plots from EIS data collected for PEDOT/GO/Dex coated Mg and Uncoated Mg. 
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3.4.3 Tafel scan 
Tafel scans represent the balance of anodic and cathodic half reactions of the corrosion reaction.  
From Tafel scans values for the corrosion current as well as corrosion potential can be 
extrapolated.  A lower corrosion current as well as a more positive corrosion potential are both 
indicative of decreased corrosion.  As can be seen in Fig. 3-3, Both PEDOT/GO and 
PEDOT/GO/Dex films show a positive shift in their corrosion potential.  In addition, both of the 
coatings show a decrease in corrosion current when compared to the Mg only sample.  The 
PEDOT/GO/Dex films do not show as significant of a positive corrosion potential shift or as 
dramatic of a decrease in corrosion current when compared to PEDOT/GO coatings.  This 
suggests the Dex loaded films are not as effective at preventing corrosion of the Mg.  The 
decrease in corrosion performance is most likely due to the addition of the Dex into the polymer 




Figure 3-3: Tafel Scan.  Current output from voltages applied during Tafel scan for PEDOT/GO on 
Mg, PEDOT/GO/Dex on Mg, and uncoated Mg. 
3.4.4 Hydrogen evolution 
Evolved hydrogen quantifies the byproduct of Mg corrosion resulting from water reduction.  
Here PEDOT/GO/Dex films act initially as a barrier layer to prevent corrosion followed by 
electrochemical coupling with the Mg to prevent further corrosion once the media inevitably 
reaches the underlying Mg.  The PEDOT/GO/Dex films resulted in a 51% decrease in the rate of 
hydrogen evolution(Fig. 3-4).  It must be noted that visible delamination of the film was 
observed on 75% of the PEDOT/GO/Dex samples within the first 24 hours.  Despite this 
delamination, the decrease in hydrogen evolution was maintained.   
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Figure 3-4: Hydrogen evolution. Evolved hydrogen from PEDOT/GO/Dex coated Mg and uncoated 
Mg. (* p>0.05, all other p<0.05) 
3.4.5 Externally powered drug release 
Powered drug release of CP Dex containing coatings on inert electrodes has shown that repeating 
reducing voltage stimulation (both biphasic and monophasic) is effective and that applying more 
negative potential results in increased drug release[100].  Here biphasic voltage stimulations are 
used to release Dex from the PEDOT/GO/Dex films on the more active Mg.  As can be seen in 
Fig. 3-5, the Dex release rate is 10 fold greater for the stimulated sample for the first 100 
stimulations.  Following this, additional stimulations result is less drug release, likely because the 
majority of the drug that was near the surface was released and the drug that is released must 
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diffuse from deeper in the film.  There is also a significant release of Dex from the non-
stimulated samples.  The initial spike in release is likely due to desorption of the loosely bound 
Dex on the surface and the following release is likely due to corrosion driven drug release 
described in 3.4.6 due to imperfect barrier properties of the PEDOT/GO/Dex film.  
 
 
Figure 3-5: Powered drug release.  Dex release resulting from applied reducing potential on 
PEDOT/GO/Dex Mg and drug release from PEDOT/GO/Dex Mg without stimulation. (* p >0.05, all other 
data p<0.05) 
3.4.6 Corrosion triggered drug release 
Here, corrosion of the exposed Mg facilitates an expedited reduction of the film and 
consequently increased drug release rates.  As can be seen in Fig. 3-6. The samples with greater 
exposed Mg had a greater release rate than those with only a small portion of Mg exposed.  Long 
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exposed samples had and average drug release rate of 3.36 µg/cm2·min for the first five minutes 
while short exposed samples had a release rate of 1.5 µg/cm2·min.  For the following 10 minutes 
long exposed samples had an average drug release rate of 3.19 µg/cm2·min while short exposed 
samples had a rate of 1.3 µg/cm2·min.  At the end of the experiment long exposed samples 
maintained an increased release rate at 1.16 µg/cm2·min while short exposed samples had a 
release rate of 0.73 µg/cm2·min.  The total release per surface area of the long exposed samples 
was significantly greater than that of the short exposed samples for the initial 30 min of the 
release experiment due to the excess current generated by the Mg corrosion.  The remaining 2.5 
hr of the release experiment showed that the long exposed samples trended to release more 
although not statistically significant.  This is firstly due to the stabilization of the corrosion of the 
exposed Mg.  Initial time points see a rapid corrosion of the exposed Mg while after 1 hr the 
corrosion has begun to stabilize.  Additionally at these later time points it is likely that some of 
the media has diffused through the PEDOT/GO/Dex coating and also begun driving release.  
Both the long and short exposed Mg has the same total coated area, and there for the total 
possible drug release from the two samples would be the same. At later time points the corrosion 
under the PEDOT/GO/Dex film is likely driving increased release of the short exposed Mg.       
PEDOT/GO/Dex on gold samples showed virtually no release of Dex. 
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Figure 3-6: Corrosion powered drug release.  Dex release from PEDOT/GO/Dex films on Mg where 
drug release is powered by Mg corrosion.  Mg samples had different amounts of exposed Mg but the same 
amount covered by the PEDOT/GO/Dex coating.  Gold samples had the same amount covered by 
PEDOT/GO/Dex and an equivalent amount of uncoated gold. (* p < 0.05, ɤ p < 0.08) 
3.4.7 Bioactivity of release Dex 
To confirm the Bioactivity of Dex released from the PEDOT/GO coatings, microglia derived 
HAPI cells were stimulated with LPS[288].  Microglia stimulation with pro-inflammatory LPS 
results in the release of a variety of inflammatory products including NO and pro-inflammatory 
cytokines.  Dex quenches the HAPI cell activation and decreases the release of NO through 
inhibiting expression of inflammatory mediators[289].    Released Dex was compared to as-
purchased Dex (this was the same source of Dex that was added to the polymerization solution 
for the polymerization of PEDOT/GO/Dex films) in its ability to suppress activity of the 
microglia.  Fig. 3-7 displays Nitric Oxide production determined by griess reagent assay.  
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Microglia stimulated with LPS bacterial derived peptide are activated to produce a fivefold 
increase in NO production as can be seen in Fig. 3-7.  Treatment with both, released and as-
purchased Dex at 5 µM suppresses microglia activation decreasing NO production.  The released 
Dex applied at the same concentration as the purchased Dex shows the same ability to suppress 
microglia activity.  This indicates that entrapment of Dex in the PEDOT/GO film on Mg and 
subsequent release did not damage the drug.   
Additionally, there was no significant difference between HAPI cells exposed to released 
or as-purchased Dex without the presence of LPS.  This indicates that the PEDOT/GO/Dex 
samples are not releasing monomers, short mer units, or GO during the stimulation that could 
generate confounding toxicity. 
 
 
Figure 3-7: Dex Bioactivity. Assessment of Dex bioactivity through quantification of NO generated 
by HAPI cells due to LPS stimulation using Griess Assay. n=4 for each group (* p < 0.05) 
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3.5 DISCUSSION 
Here we utilize a PEDOT/GO/Dex composite coating to both control Mg corrosion as well as 
release bioactive cues in a smart self-powered way.  A coating with these two properties, 
corrosion control and smart self-powered drug release, could aid in the clinical implementation 
of Mg based implants.  Our composite coating takes advantage of the beneficial properties of 
both of these components for use as a responsive corrosion control and drug releasing coating.  
The coating prevents corrosion as an initial barrier layer.  Following eventual diffusion of the 
corrosion media through the film, the properties of the film will both passivate the corroding 
location, as described in chapter 2, and locally release anti-inflammatory drugs in the area of 
corrosion.  The galvanic coupling of PEDOT/GO/Dex to the Mg corrosion current facilitates the 
release of Dex in the areas where corrosion is occurring.  This PEDOT/GO/Dex coating system 
aims to combat the potential negative effects of increasing pH local to the corroding Mg implant 
as well as gas pockets resulting from the evolved hydrogen by both decreasing corrosion and 
improving tissue health near sites when corrosion does occur.    
Polymerizing the PEDOT/GO/Dex film directly on the Mg allows it to act as a corrosion 
inhibitor similarly to the PEDOT/GO coating discussed in Chapter 2.  The PEDOT/GO/Dex 
coating showed improved barrier properties over uncoated Mg as indicated by EIS measurements 
(Fig. 3-2).  Tafel scan data (Fig. 3-3) also showed corrosion protection provided by 
PEDOT/GO/Dex coatings, albeit not as significant as PEDOT/GO alone.  The lower corrosion 
protection provided by PEDOT/GO/Dex is also noted in the hydrogen evolution experiments 
(Fig. 3-4) where 75% the PEDOT/GO/Dex films showed film delamination within the first 24 
hours of immersion in PBS.  Despite this delamination, over the following 17 days, the 
PEDOT/GO/Dex films maintained a decreased rate of hydrogen evolution (Fig. 3-4).   This 
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indicates that the electrochemical coupling of the PEDOT/GO/Dex films and the Mg was 
maintained.  This electrochemical coupling provides improved corrosion protection even if areas 
of the film begin to delaminate.  The combination of expedited film delamination observed 
during hydrogen evolution experiments as well as decreased corrosion protection assessed 
through EIS and Tafel scans indicates that the PEDOT/GO/Dex coating is not as effective at 
preventing corrosion as the PEDOT/GO coatings without Dex.  This is due to the imperfect 
barrier layer of the PEDOT/GO/Dex film resulting from the added Dex.  The Dex is incorporated 
into the film both by being trapped in the polymer matrix during polymerization, as well as being 
carried into the film by GO discussed below.  This results in a barrier film that has Dex 
interrupting the PEDOT/GO film.  These disruptions are vulnerable locations where the 
corrosion media can more easily diffuse through the coating.  The barrier properties are likely 
further decreased as the Dex leaves the film, through diffusion in addition to being driven out by 
the corrosion current.   
Corrosion triggered drug release from CPs has been shown previously with active metals 
wired to the CP acting as a power source.  In one study, CP doped with negatively charged 
phenol red was electrically connected to a zinc anode and both were placed in aqueous 
media[290, 291].  Oxidation of the zinc in water generated negative current that reduced the CP 
and drove drug release. In another study, external coupling of Mg corrosion for drug release was 
shown when the corroding Mg was wired to a CP/Dex coating and both were placed in an 
aqueous media[292].  These cases both did not place the CP film directly on the corroding metal, 
instead the corroding metal was wire connected to the CP film that was deposited on an inert and 
stable substrate.  Controlled release of adenosine triphosphate from CP has been shown where 
Mg is sputtered onto the polymer film and the corrosion of the thin Mg layer drives the 
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release[293, 294].  Here however, the Mg was purely sacrificial and served only to power release 
from the CP. 
 Different from the above studies, PEDOT/GO/Dex was directly deposited on active Mg 
and self-powered drug release was achieved.  Common CP drug releasing systems often utilize a 
negatively charged drug that is incorporated with the positively charged backbone of the CP.  
Upon reduction, the CP backbone is neutralized and the positive charge that prevented diffusion 
out of the film drug in is eliminated allowing the drug to diffuse out of the film.  Here however 
we were unable to use a negatively charged drug molecule due to the induced aggregation of the 
GO sheets due to the positive charge of the drug salt, in this case dexamethasone 21-phosphate 
disodium salt[100, 102].  The positive charge results in a shrinking of the electric double layer 
the keeps the GO sheets suspended in solution resulting in GO aggregation[295].  To prevent 
aggregation, Polymerization of the PEDOT/GO/Dex films was accomplished using a non-salt 
form of Dex in the ethanol based PEDOT/GO solution discussed in chapter 2. Without the 
negative charge, the Dex will not be loaded and released from the polymer film in the traditional 
CP dopant release paradigm.       
Here, incorporation of the Dex into the polymer is facilitated both by entrapment during 
the polymerization as well as bonding of Dex with the GO sheets.  The bonding is possibly 
facilitated by hydrophobic π-π stacking between the aromatic rings on the Dex and GO as well as 
hydrogen bonding between hydroxyl groups of Dex and GO.  Once attached, the Dex can be 
carried into the PEDOT film with the GO that acts as the dopant[278, 280-282]. 
  Application of external voltage stimuli resulted in well controlled Dex release (Fig. 3-5).  
This externally powered reduction of the PEDOT/GO/Dex film releases the entrapped uncharged 
Dex through multiple mechanisms.  Firstly, reduction can interfere with the π-π stacking of the 
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Dex and GO[296].  Here the reduction interferes with the quadrapole established by the aromatic 
rings which drive π-π stacking[297].   Also, reduction of the polymer may reduce some of the 
GO resulting in less hydroxyl groups expressed.  This could minimize hydrogen boding between 
the Dex and GO[278].  Both the interference of the π-π stacking and loss of hydrogen bonds 
eliminate the forces holding the Dex in the film causing it to be released.  Additionally, reduction 
of CP films causes significant volume changes as solvent is transported in the film changing the 
arrangement of the polymer chains and causing ion transport in and out of the film to compensate 
for the charge change[298]. This volume change has also been shown to release drug from CP 
films [113, 299], and may be another method for the release of non-charged Dex from the 
PEDOT/GO/Dex film.    
Drug release was also accomplished without the application of external power, but 
through the coupling of the PEDOT/GO/Dex coatings and current generated by Mg oxidation.  
As can be seen in Fig. 3-6, samples with more exposed Mg showed increased total drug release 
as well as increased drug release rates.  This is due to greater amount of exposed Mg providing 
more surface area for corrosion.  More electrons are therefor generated on large exposed Mg 
samples and these electrons further reduce the polymer resulting in greater drug release.  Self-
powered on demand drug release of anti-inflammatory Dex in the area of Mg corrosion could 
help combat local tissue response to increase pH and gas pocket formation that can prevent 
proper healing and tissue interfacing with the device.  The increase in drug release with 
increasing exposed Mg did not however did not correlate with the total exposed surface area.  
Those samples with 1 mm exposed Mg did not have 11 times less drug release than those 
samples with 11 mm exposed Mg.  This is likely due to the poor barrier properties of the 
PEDOT/GO once the Dex is added.  Consequently, while corrosion is occurring at the exposed 
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Mg, there is also corrosion occurring underneath the PEDOT/GO/Dex film.  This corrosion 
drives drug release and this local corrosion may be more efficient at driving release from the 
polymer as opposed to the more distant corrosion of the exposed Mg.  For those reasons, the 
short exposed Mg samples did result in increased drug release compared to controls while 
releasing ~50% less drug than the long exposed Mg samples.  
Of paramount importance with drug releasing systems is the viability of the drug 
following release[100]. During electropolymerization, Dex is exposed to ethanol and oxidizing 
potentials that could damage the bioactivity of the drug release from the PEDOT/GO/Dex 
coating.  The quenching of the activity of HAPI cells exposed to LPS by the released Dex 
confirms that the bioactivity of Dex in the PEDOT/GO/Dex coating is maintained.  While the 
LPS stimulation of HAPI cells shows the Dex is bioactive, the pathway activated by the LPS 
stimulation is that of the Pathogen-Associated Molecular Pattern (PAMP)[300].  It may be useful 
to also look at the effect of released Dex on the Damage-Associated Molecular Patter (DAMP) 
which may be more representative of the cellular response around an implanted device[300].  
This self-powered drug releasing paradigm has the potential to also be used for other drugs such 
as bisphosphonate molecules for orthopedic implants[301] and Sirolimus and Paclitaxel for stent 
applications[302-304].  In addition, the drug release rate could be tuned to provide optimal 
release paradigm for each specific application through sonication of the GO to alter the amount 
of drug that is loaded into the film as well as the release kinetics[102]. 
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3.6 CONCLUSION 
Mg corrosion, while being ideally safe, has shown local tissue damage through increases in pH 
and gas pockets resulting from hydrogen evolution if corrosion is too fast or if the byproducts 
cannot be cleared easily.  The PEDOT/GO/Dex coating developed here provides both corrosion 
protection and as serves as a smart drug release system that actively responds to Mg corrosion.    
This PEDOT/GO/Dex coating controls corrosion through initial barrier properties followed by 
coupling of the redox properties of film to generate a more corrosion resistant intermediate. In 
addition to corrosion protection, when corrosion inevitably does occur, anti-inflammatory drugs 
are locally released to minimize detrimental effects on the surrounding tissue.  This single layer 
dual function approach will serve to bring Mg closer to clinical applications by providing 
corrosion control and the ability to locally release biologically relevant molecules 
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4.0  PEDOT/GO COATINGS AS A METHOD FOR ADDING BIO-FUNCTIONAL 
SURFACE CUES  
4.1 ABSTRACT 
Magnesium’s corrosion in vivo has the potential to make it a useful material for constructing 
biomedical implants that do not need to be surgically removed but simply degrade away once the 
tissue has healed.  Magnesium however lacks a versatile method of functionalizing the surface 
with biomolecules that could guide improved local tissue response.  Here we report on the 
coating of Mg with conducting polymer 3,4-ethylenedioxythiphene (PEDOT) and graphene 
oxide (GO) composite coating.  This coating provides carboxylic acid groups on its surface that 
can be used to facilitate attachment of biomolecules with primary amines through carbodiimide 
crosslinking chemistry.  Here we explore the attachment of different molecules to the surface in 
order to determine if this coating could function as a versatile platform for adding various 
surface cues on Mg implants. Albumin-fluorescein protein complex, amine functionalized poly 
ethylene glycol(PEG), nerve growth factor (NGF), and a novel super oxide dismutase mimic 
with amine functionalization (iSODm) were covalently attached through this carbodiimide 
crosslinking chemistry.  Attachment of fluorescently tagged albumin confirmed the covalent 
attachment of molecules to the surface.  PEG functionalized surfaces showed decreases in 
attachment of both fibroblast cells and Escherichia coli (E. coli) bacteria.  Surfaces 
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functionalized with NGF showed the ability to increase neurite outgrowth of PC12 cells.  
Attachment of iSODm was confirmed as its antioxidant behavior was maintained and it resulted 
in increased mortality of bacteria attached to the surface.  These results suggest that the 
PEDOT/GO coating has the potential to be a versatile method of attaching surface cues to Mg 
implants to help guide tissue response and improve patient outcomes.         
4.2 INTRODUCTION 
4.2.1 Problems that can be addressed by surface functionalization 
Biomedical implants suffer from multiple issues in regards to integration with the host tissue.  
Firstly, as with all medical implants, there is an inherent risk of infection.    Complications 
associated with implant infection often lead the need for implant removal[305].  In addition to 
infection, implanted devices suffer from both acute and chronic inflammation.  Acute 
inflammation, resulting from the trauma of implantation procedure can, in some cases, be severe 
enough to warrant removal of the device[306].  Chronic inflammation has been the target of 
recent research to prevent the loss of implants which are designed to remain in vivo for the 
patient’s lifetime[307].  The chronic foreign body reaction (FBR) is classified by persistent 
inflammation and recruitment of macrophages, monocytes, and lymphocytes to the implant 
location and can be another cause for implant removal[308, 309].  In addition to infection and 
inflammation, which are applicable to all implanted devices, there are certain device and tissue 
specific issues that result device failure. Stent failure results from restenosis and thrombosis 
[310], orthopedic implant failure is caused by a lack of osseointegration[311], and the slow rate 
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of axonal regeneration in nerve conduits prevents functional recovery for long gap injuries [312-
316]. One method that can be utilized to combat these complications is the use of surface 
immobilized bioactive factors to improve tissue specific reactions local to the implant[317-320]. 
4.2.2 Prevention of infection  
Bacterial or fungal colonization of the device can be introduced during the implantation 
operation from sources including ambient air, contamination from the surgical staff or 
equipment, bacteria residing on the patient’s skin, and bacteria found in the patient’s body[321, 
322].  These organisms adhered to the implant are often embedded in an extracellular matrix 
which shields them from the host’s immune systems as well as decreases the potency of 
administered antibiotics[311].  To prevent bacteria or fungi colonization, surface coatings that 
prevent attachment are being developed.  Most notably is the use of polyethylene glycol (PEG).   
Kingshott et al. showed that the technique used to covalently immobilize PEG played a 
significant roll in the resulting the effectiveness of PEG at preventing bacterial adhesion[323]. 
PEG Coatings with utilizing a combination of steric hindrance and anti-adhesion surface charge 
have shown the ability to prevent bacterial adhesion[324].  Coatings incorporating PEG while 
also presenting the RGD (Arg-Asp-Gly) adhesion peptide prevented bacterial (staphylococcus 
aureus) adhesion while maintaining fibroblast and osteoblast cell adhesion[325].  These reports 
suggest that a PEG surface coating could provide antibacterial properties to prevent biofilm 
formation and decrease infection risk. 
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4.2.3 Mitigation of inflammation 
The FBR is another issue that could potentially be ameliorated by the application of a surface 
coating on the implant.  Upon implantation, the device is immediately covered by proteins from 
the patient’s blood and tissue that nonspecifically adsorb to the surface. The degree of 
nonspecific adsorption can be correlated with the degree of biocompatibility of the implant[307].  
An immune and inflammatory response involving leukocytes and neutrophils then takes 
place[326].  Monocytes and macrophages begin to interact with the implant, where the 
composition of the non-specifically adsorbed proteins can affect macrophage phenotype[326].  
Macrophages are considered the key mediators of the FBR in that they generate both 
inflammatory and regenerative products[326].   Chronic presences of the foreign body results in 
the fusion of macrophages into foreign body giant cells which contribute further to 
inflammation[327]. Additionally, fibroblasts are recruited to the implant area and generate a 
fibrous capsule to isolate it from the native tissue[251].  This FBR of chronic inflammation and 
fibrous encapsulation impedes device-tissue integration.   
While coatings that release anti-inflammatory and other drugs to minimize FBR have 
been investigated [113, 326, 328-330], the finite reservoir of drug contained in a surface coating 
limits this technology’s applications for chronically implanted devices.  For this reason different 
coatings that alter the surface chemistry of the implant have been investigated.  These coatings 
attempt to interfere with the initial nonspecific adsorption of proteins which literature suggests 
guides the remainder of the FBR[326].  Currently, PEG surfaces, like those used to decrease 
bacterial adhesion, are one of the more promising surfaces for prevention of the non-specific 
protein adsorption[331]. Also, coatings of collagen and PLA scaffolds have shown decreased 
FBR and increased angiogenesis around the implant[332, 333]. A variety of hydrogel coatings 
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have also been investigated to improve implant performance through decreasing the effects of 
the FBR[334-336].   While these coatings have shown in vitro promise, in vivo improvements of 
the FBR have been mixed.   
  Also, heparin coatings have been shown to reduce adsorption of multiple different 
proteins in the inflammatory pathway including fibronectin, fibrinogen, kininogen, and 
complement 3 protein from whole blood[337].  Immobilization of anti-inflammatory peptide 
Alpha-MHS on neural electrodes reduced inflammation through altering the activity of glia 
response surrounding the implant[338].  Covalent immobilization of anti-inflammatory cytokines 
was accomplished with a fusion protein of recombinant human IL-1 receptor antagonist and 
elastin-like peptide and significantly changed the behavior of LPS stimulated monocytes[339].    
Exposure to this protein decreased monocyte differentiation and expression of pro-inflammatory 
cytokines and caused an increase in anti-inflammatory and pro-wound healing cytokines.  
Additionally, the surface modification of samples with a superoxide dismutase mimic (SODm) 
can minimize the harmful environment around an implant by eliminating the powerful oxidant 
superoxide which is released by macrophage and glia[340, 341]. The acute and chronic tissue 
response to polyethylene samples modified with SOD displayed decreased inflammatory 
response characterized by neutrophil migration, presence of foreign body giant cells, and fibrous 
encapsulation[342]. 
4.2.4 Implant specific cues 
In conjunction with infection and inflammation, implant performance could be enhanced through 
the addition of further surface cues to encourage appropriated local tissue response to the 
implant.  In the case of orthopedic implants, ossiointegration, or bone growth and remodeling 
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around the implant, to form a tight junction between the bone and implant is desired.  To 
accomplish this, different surface roughening and calcium based coatings have been 
investigated[311, 343].  In addition to these non-biologic coatings, surface functionalization of 
biomolecules has been shown to improve implant outcomes.  Adhesion promoter RGD (Arg-
Gly-Asp) increased adhesion of osteoblasts in vitro which could facilitate improved bone 
regrowth around the implant[344].   In vivo RGD surface functionalized samples doubled the 
amount of bone interfacing with the functionalized implants as well as decreased fibrous tissue 
formation and increase in bone density surrounding the implant[345].  Implants functionalized 
with GFOGER, a peptide mimicking a binding loci of collagen, stimulated osteoblast 
differentiation through α2β1 integrin binding mediated pathway resulting in increased the 
amount of bone contacting the implant[346].  Growth factors such as bone morphogenic protein 
(BMP) have also been covalently immobilized and resulted in increased bone density adjacent to 
the implant[347].  
Stents too could benefit from tissue specific surface immobilization to combat issues such 
as thrombosis, re-stenosis, and endothelialization.  Heparin modified stents have a significantly 
lowered the activation of platelets and coagulation and decreased the expression of GP IIb/IIIa, 
αIIbβ3 on platelets, an integrin required for normal platelet aggregation[348, 349].  Immobilized 
heparin has also suppressed the adsorption/activation of procoagulant proteins and enhanced the 
adsorption/activation of anticoagulant proteins[350].  Phosphocholine, a zwitterionic molecule, 
has been immobilized on stents and resulted in reductions in platelet adhesion and 
activation[351, 352].  Surface modification with the apyrase enzyme was able to catalytically 
degrade ADP preventing the recruitment and aggregation of platelets on the surface[353]  
Attachment of collagen binding peptides to the surface allowed collagen attach and mask the 
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implant, preventing platelet adhesion and activation[354].  In addition to preventing thrombosis, 
surface functionalization has been used to prevent restenosis.  Estrogen functionalized surfaces 
have been shown to increase intracellular cyclic AMP which in turn decreases synthesis rates in 
vascular smooth muscle cells[355].  Methods for inhibiting platelet-derived growth factor have 
also been investigated towards decreasing restenosis[356].  In contrast to sequestering restenosis, 
encouraging proper endothelialization of stents has also been linked to improved outcomes.  
Surface immobilization of vascular endothelial growth factor significantly increased the 
attachment of endothelial cells[357]. Attachment of anti-CD34 antibody showed specific 
adhesion promotion of vascular endothelial cells through binding the CD32 transmembrane 
protein resulting in increased vascularization of the stents[168].  Immobilization of REDV 
peptides, complement to endothelial integrin, selectively increased endothelial cell growth on the 
surface[358].  
Similar to the above two applications, peripheral and central nerve regeneration could 
benefit from implants that degrade over time but also have functional cues to encourage rapid 
nerve growth as well as guide nerves to the proper target location.  A variety of peptide 
sequences derived from the extracellular matrix have been investigated including CDPGYIGSR, 
GQAASIKVAV, GRGDS, and PHSRN[359].  Hydrogels modified with CDPGYIGSR and 
GQAASIKVAV peptides improved adhesion of dorsal root ganglia (DRG) neurons as well as 
reported neurite growth into the functionalized scaffolds indicating the ability of peptides to  
promote neurite guidance [360]. Patterns of GRDGS placed on a modified agarose hydrogel 
encouraged preferential attachment of dorsal root ganglia cells and guided neurite outgrowth 
along the RGDGS paths [361].  Similarly, IKVAV peptide, bound to a hydrogel via streptavidin-
biotin mechanism, encouraged selective adhesion of primary hippocampal neurons with neurons 
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sprouting neurites along the functionalized route and developing functional synapses[362].  In 
addition to adjusting the substrate surface to promote neural health, gradients of the extracellular 
matrix protein laminin have been immobilized on surfaces to directing neurite growth up the 
concentration gradient [363].   These surface functionalization techniques provide promising 
outlook for the implementation of nerve regeneration materials that not only can improve neuron 
interaction with the device, but can functionally guide neurons to the correct target. 
4.2.5 EDC-NHS linking 
One convenient method for attaching different biomolecules to a surface is through the use of 
carbodiimide crosslinking.  Here the carbodiimide group 1-ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) serves to link primary amine (-NH3) groups present on many 
biomolecules, to a carboxylic acid group (-COOH) on the substrate surface[364].  The 
carbodiimide reacts with the surface bound –COOH to form an O-acylisourea, which is easily 
displaced by the primary amine resulting in an amide bond.  This O-acylisourea intermediate is 
however not stable, so the addition of N-hydroxysuccinimide (NHS) has been added to the 
linking step.  The NHS group reacts with the O-acylisourea to form a more stable ester that still 
allows the anchoring of primary amines.  This technique has been used to attach many bioactive 
molecules including proteins[365, 366], peptides (IKVAV, RGD, or YIGSR)[367, 368], active 
enzymes[369], and aptamers[370] to name a few.   Here we utilize the CP coating PEDOT/GO 
on Mg to provide the –COOH groups that can be utilized for EDC-NHS chemistry.  The –COOH 
groups are present on the surface of the PEDOT/GO film due to the edges of the GO sheets being 
exposed at the surface[103].  EDC-NHS chemistry can then be conducted linking the –COOH on 
the surface to primary amines of different bioactive molecules. 
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   Here we report on the exploration of different functional groups attached to 
PEDOT/GO on Mg through EDC-NHS that may be used in the future to improve implant 
performance.  PEG functionalization of the PEDOT/GO film showed significant decrease in the 
number of fibroblast cells and E. coli bacteria attached.  Functionalization of the PEDOT/GO 
surface with Nerve Growth Factor (NGF) promoted neurite outgrowth from PC12 cells.  
Additionally, the immobilization of a novel super oxide dismutase mimic (iSODm) showed the 
ability of the functionalized surface to decrease the presence of harmful super-oxide reactive 
oxygen species and suppress inflammation.  The iSODm surface also caused an increase in 
mortality of E. Coli on the surface.   These results show that the PEDOT/GO coating on Mg can 
provide a variety of surface cues to guide implant specific tissue responses.   
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Single layer graphene oxide sheets were purchased from Cheap Tubes (Cambridgeport, VT).  
200 proof ethanol was purchased from Decon Labs Inc. (King of Prussia, PA).  Magnesium 
ribbon ≥99.5% (3 mm wide x 0.2 mm thick), 3,4-Ethylenedioxythiphene (EDOT) monomer, 
xanthine, xanthine oxidase from bovine milk, catalase from bovine liver, cytochrome C from 
equine heart, N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydro-chloride, N-
Hydroxysuccinimide, and albumin-fluorescein isothiocyanate conjugate were purchased from 
Sigma-Aldrich.  Amine functionalized poly ethylene glycol (2000 molecular weight) with a 
hydroxyl terminal was purchased from JenKem Technologies (Beijing, China).  Kwiksil silicone 
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elastomer was purchased from World Precision Instruments(Sarasota, FL). PBS 10x concentrate 
(136 mM NaCl, 2.7 mM Potassium chloride, 10 mM Phosphate Buffer) was purchased from 
EMD Millipore (Billerica, MA) and diluted using de-ionized water from a Millipore Milli-Q 
system.  BacLight bacterial Live/Dead stain, Live/Dead Viability/Cytotoxicity for mammalian 
cells stain, yeast extract, tryptone, and sodium chloride were purchased from Fisher Scientific.  
NIH-3T3 fibroblasts (CRL-1658), Dulbecco’s Modified Eagle’s Medium (30-2002), Bovine calf 
serum, PC12 cells (CRL-1721), RPMI-1640 Medium (30-2001), heat- inactivated horse serum, 
fetal bovine serum, Escherichia coli (11775) were purchased from ATCC (Manassas, VA). 
iSODm was custom synthesized in our lab by Dr. Noah Snyder[371].  
4.3.2 Polymerization of PEDOT/GO film 
GO was added to ethanol at a concentration of 10 mg/ml and the resulting solution was sonicated 
for 30 minutes in a bath sonicator FS110H (Fisher Scientific).  Following sonication, 20 µl/ml 
EDOT and 35 µl/ml deionized water were added into the GO ethanol solution to create the 
polymerization solution. The Mg ribbon was cut into 2 cm long strips, rinsed with ethanol, and 
blotted dry.  Polymerizations, and all electrochemical measurements, were conducted on a 
Gamry Potentiostat FAS2/Femtostat using Gamry Framework Software (Warminster, PA).  
Polymerization consisted of a two-electrode system with Mg ribbon working electrode and a 
gold counter/reference electrode.  Polymerization was conducted in 300 µl of fresh 
polymerization solution and a potential of 0.6 V vs. counter was applied until a charge of 10 mC 
was reached.  Coated length was 9 mm.  Following polymerization, electrodes were gently 
dipped in ethanol then dried at -20oC for two days, followed by drying at 3oC for one day.  
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Following this drying process, the PEDOT/GO forms a thin adherent black film on the Mg 
ribbon.  Samples were stored at ambient temperature following drying process. 
4.3.3 EDC-NHS functionalization 
EDC-NHS functionalization was conducted in a 50% ethanol solution with 0.1 M EDC and 0.1 
M NHS.  Functionalization was carried out for 15 minutes followed by an ethanol rinse and a 
brief air dry.  The samples were then exposed to the moiety desired for attachment for another 15 
minutes.  For albumin-fluorescein isocyonate conjugate, 20 µg/ml in DiH2O was exposed to the 
surface, followed by a rinse with DiH2O. NGF functionalized samples were exposed to 20 µg/ml 
NGF.   
iSODm and PEG were functionalized in one step where the EDC-NHS solution also 
contained the moiety for attachment for a total of 30 minutes. Amine functionalized PEG was 
added to the EDC-NHS solution at 40 µg/ml. iSODm was added to the EDC-NHS solution at 0.8 
mg/ml.  Following functionalization, samples were rinsed with ethanol and air dried. 
4.3.4 NIH-3T3 fibroblast 
NIH-3T3 cells were cultured in Dulbecco’s Modified Eagle’s Media supplemented with 10% 
bovine calf serum.  Cells were maintained in 75 cm2 culture flasks and passaged at ~80% 
confluence.   
PEDOT/GO on Mg samples were functionalized with PEG as described in section 4.3.3.  
Non-functionalized PEDOT/GO on Mg was used as the control. 2 cm long Mg strips coated 9 
mm with PEDOT/GO, either PEG functionalized or non-functionalized, were cut to a total length 
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of 10mm resulting in 9mm of PEDOT/GO coating with 1mm of exposed Mg for handling.  Mg 
samples were individually placed into 24 well plates.  The samples were affixed to the base of 
the plate using   Kwiksil silicone ensuring to completely cover the 1mm exposed section.   
10 µl culture media containing 10,000 cells were placed on the samples and allowed to sit 
for 15 minutes.  Following this 1.5 ml of culture media was added to the well.  Cells were 
cultured for 24 hr and then stained with live dead staining. 
4.3.5 Live dead stain 
Mg samples were removed from the well plate and placed in to the staining solution of 2 µM 
calceinAM and 2 µM ethidium homodimer-1 in PBS and incubated for 10 min.   After 
incubation, images at 10x were taken on a Zeiss Axioskop 2 Mat Fluorescent microscope.  Cells 
were counted manually using ImageJ and ‘Cell Counter’ add-on by Kurt De Vos. 
4.3.6 PC12 cell culture 
PC12 cells were cultured in ATCC RPMI-1640 media supplemented with 10% heat inactivated 
horse serum and 5% fetal bovine serum.  Prior to plating on samples for analysis of neurite 
extension, PC12 cells were cultured in the flask for two days with 10ng/ml NGF added to the 
media.  This serves to prep the cells prior to plating on the samples so that the response to NGF 
can be expedited.  PEDOT/GO on Mg was functionalized with NGF as described in section 
4.3.3.  Samples were then cut, resulting in 1 cm long samples with 9 mm PEDOT/GO coated and 
1 mm uncoated.  The samples were affixed to the bottom of a 24 well plate using Kwiksil 
silicone ensuring to cover completely the small uncoated portion.  Control cells were plated on 
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collagen IV coated 24 well plates. Throughout the 4 day experiment, samples were then either 
stained with live dead stain 4.3.5 or fixed for SEM 4.3.7. 
4.3.7 Cell Fixation for SEM 
PC12 cells cultured on PEDOT/GO Mg substrates with and without EDC-NHS functionalization 
of NGF were fixed in 4% paraformaldehyde for 30 minutes.  Following fixation cells were rinsed 
with ethanol three times allowing each rinsing solution to sit for 10 minutes.  Ethanol was 
removed and the samples were allowed to air dry overnight.  Samples were placed in a desiccator 
for 12 hours followed by a vacuum desiccator for 12 hours prior to SEM imaging.  The cells 
were sputtered with 3 nm gold prior to imaging and were imaged using JEOL JSM 6330F. 
4.3.8 Cytochrome C assay 
Reaction solution consisted of 1 mg/ml cytochrome C, 0.5 mg/ml Catalase, 0.05 mg/ml xanthine, 
and 0.05 mg/ml xanthine oxidase.  Control solution was the reaction solution without xanthine 
oxidase.  Solutions were placed in a 96 well plate and monitored using Spectromax i3x at the 
characteristic absorbance of ferrocytochrome C 550nm.  After ~5 min, when the control solution 
absorbance had plateaued, PEDOT/GO coated Mg samples, with and without iSODm 
functionalization, were placed in the well.  Every 5 min for the next 20 min samples were 
removed from the wells and absorbance was tested. 
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4.3.9 Bacteria culture 
Lysogeny Broth consisted of 10 g tryptone, 5 g yeast extract, and 10 g NaCl in 950 mL deionized 
water and was autoclaved prior to use.  E. coli bacteria powder was placed into ~9 ml of 
Lysogeny Broth and cultured in a Forma Orbital Shaker incubator overnight.  E coli were diluted 
to reach and optical density of 0.8 at 600nm, assessed on Spectromax i3x. They were then plated 
on PEDOT/GO Mg samples with and without iSODm functionalization that had been affixed to 
the base of a 24 well plate as described in section 4.3.4 in 300 µl total volume.  Following a 12 
hour static settlement, samples were stained with Live/Dead BacLight stain by removing 50% of 
the culture media in the wells and replacing it with the staining solution as per the 
manufacturer’s instructions (6µM SYTO 9 stain and 30µM propidium iodide in PBS).  
Following 15 min incubation, the media was removed and rinsed three times with PBS.  Mg 
samples were then removed from the well plate and dipped three times in PBS to remove any 
loosely adhered cells.  Excess PBS was then wicked away with kimwipe.  Imaging was 
conducted immediately using a Leica DMI 4000 B inverted fluorescent microscope.  Cells were 
counted manually using ImageJ and ‘Cell Counter’ add-on by Kurt De Vos. 
4.4 RESULTS 
4.4.1 Albumin-Fluorescein 
To demonstrate the ability of EDC-NHS chemistry to covalently attach components with amine 
functional groups, albumin-fluorescein complex was tested.  Here the albumin has amine groups 
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on the N-terminus of the peptide chains as well as on amino acids lysine, asparagine, and 
glutamine.  As can be seen in Fig. 4-1 below, the PEDOT/GO sample without EDC-NHS 
treatment has only areas where large aggregates of protein adsorbed to the surface.  The sample 
that treated with EDC-NHS prior to protein exposure is completely covered in the green 
fluorescent glow due to the attached albumin.  This suggests that the EDC-NHS functionalization 
covalently attached the amine groups of the albumin to the exposed carboxylic acid groups of 
GO sheets protruding from the polymer surface. 
 
 
Figure 4-1: Albumin-Fluorescein surface attachment. (A) PEDOT/GO on Mg that did not have EDC-
NHS treatment prior to exposure to Albumin tagged with fluorescein. (B) PEDOT/GO on Mg that did have 
EDC-NHS prior to exposure to Albumin tagged with fluorescein. Scale bar 20 µm 
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4.4.2 NIH 3T3 Fibroblast attachment 
To test the ability of PEG functionalized PEDOT/GO to prevent cell attachment, the adhesion of 
Fibroblast cells was tested.  Fibroblasts plated on PEG functionalized PEDOT/GO Mg samples 
showed an 81% decrease in the number of attached cells.  Additionally those cells that did attach 
showed less extending of processes indicating that the PEG functionalized surface was not 
conducive to cell attachment and spreading. 
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Figure 4-2: NIH 3T3 on PEG surface. (A) 10x image showing fibroblasts attached to adsorbed PEG 
PEDOT/GO Mg samples stained with calcein AM (B) 10x image showing fibroblasts attached to EDC-NHS 
attached PEG PEDOT/GO Mg samples (C) Counting of cells on PEG adsorbed and PEG functionalized 
samples. Scale bar 250 µm (* p < 0.05)  
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4.4.3 PC12 cell attachment and neurite sprouting  
Representative images illustrating the neurite sprouting from PC12 cells on collage IV with and 
without NGF supplemented culture media can be seen in Fig. 4-3. Without NGF exposure, the 
PC12 cells exhibited very little spreading and process extension(Fig. 4-3).  In contrast, PC12 
cells with NGF supplemented media displayed increased spreading, neurite sprouting, and 
increased neurite length. NGF also increased the number of cells extending multiple processes 
(Fig. 4-3 B). 
 
 
Figure 4-3: PC12 control culture. Images of PC12 cells culture on collagen IV coated wells (A) 
without NGF in the culture media, and (B) with the addition of 10 ng/ml NGF in the culture media after 3 
days in culture.  Scale bare = 50 μm 
  
To investigate the ability of surface cues immobilized on PEDOT/GO to drive cell 
specific behavior, NGF was attached to the PEDOT/GO through the EDC-NHS protocol.  PC12 
cells cultured on NGF functionalized PEDOT/GO substrates showed sprouting of processes 
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indicative of their response to the surface immobilized NGF.  Over the course of 4 days PC12 
cells showed increasing process outgrowth as can be seen in Fig. 4-3.  Cells on NFG 
functionalized PEDOT/GO imaged at 1 day (4-3 A) showed no process sprouting while at 2 days 
(4-3 C) processes can be seen and at 4 days (4-3 E and F) multiple processes and processes of 
increasing length can be observed.  Cells on non-functionalized PEDOT/GO did not show 
evidence of neurite sprouting (Fig 4-3 B, D, and G).  
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Figure 4-4: PC12 Cell culture. PC12 cells cultured on NGF functionalized and adsorbed PEDOT/GO 
Mg samples over the course of 4 days imaged with calcein AM stain.  (A) Cells imaged after 1 day in culture 
on NGF functionalized samples. (B) Cells imaged after 1 day in culture on NGF adsorbed samples. (C) Cells 
imaged after 2 days in culture on NGF functionalized samples. (D) Cells imaged after 2 days in culture on 
NGF adsorbed samples. (E & F) Cells imaged after 4 days in culture on NGF functionalized samples, and (G) 
samples cells imaged after 4 days in culture on NGF adsorbed samples. Scale bar 50 µm 
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SEM imaging was used to more closely observe the PC12 cell morphology and neurite 
sprouting on the surface of NGF functionalized and NGF adsorbed PEDOT/GO surfaces. Images 
of the PC12 cells on NGF functionalized substrates can be seen in Fig. 4-5 (A, C, and E).  In Fig. 
4-5 A, a larger cluster of PC12 cells on an NGF functionalized surface exhibit increased 
spreading as well as increased neurite sprouting compared to the cluster of cells on the NGF 
adsorbed surface (4-5 B) which are more rounded with less spreading and less neurite sprouting.  
This lack of neurite sprouting and more rounded morphology is again seen on the NGF adsorbed 
surface in Fig. 4-5 D.  Figure 4-5 C and E show additional examples of neurite sprouting on the 
NGF functionalized surface.  In 4-5 C, it can be seen that the cell in the lower portion of the 
image is extending a neurite upward while several smaller neuritis are extending downward.  In 
4-5 E, the remains of a larger neurite process can be seen.  While a cell fixation method has been 
developed to preserve cell structure under the high vacuum of the SEM, these protocols involve 
extended duration soaking in a variety of media.  To prevent excessive corrosion of the samples 
during the fixation, the procedure was expedited which may have resulted in destabilization of 
the cells on the surface of the substrate causing some cells to be removed from the surface.  This 





Figure 4-5: PC12 SEM. SEM images of PC12 cells cultured on EDC-NHS functionalized or adsorbed 
PEDOT/GO substrates for 3 days. (A) Cluster of cells on NGF surface showing increased cell spreading and 
increased neurite sprouting.  (B) Cluster of cells on adsorbed surface where cells are more rounded indicating 
less spreading and display less neurite sprouting. (C) Image on NGF surface showing neurite sprouting 
between cells. (D) Cells on NGF adsorbed surface showing less neurite sprouting.  (E) A larger neurite 
remaining on the NGF-functionalized surface. In this case, the cell body was likely removed during the 
expedited drying process that was used to minimize corrosion during fixation and drying. 
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4.4.4 Cytochrome C Assay 
Testing the activity of PEDOT/GO functionalized with iSODm requires the generation of super 
oxide as well as its quantification which is difficult due to super oxide’s short half-life and 
reactivity[372].  The reaction of xanthine with xanthine oxidase results in the production of 
superoxide which can be quantified as the superoxide reduces cytochrome c to ferrocytochrome 
c which has a characteristic absorbance at 550 nm[373].  As a result of iSODm immobilized on 
the surface of the PEDOT/GO Mg samples, the amount if cytochrome C that was reduced 
decreased when a PEDOT/GO/iSODm sample was placed in the super oxide generating and 
cytochrome C containing solution.  This can be seen in Fig. 4-3 where the absorbance recorded 
when iSODm functionalized samples were placed is significantly lower than both those solutions 
that had no sample as well as those solutions that had non functionalized PEDOT/GO Mg.  After 
just 5 minutes of the iSODm functionalized sample being immersed in the superoxide generating 
solution, the amount of superoxide that had been generated decreased 55.5%. Over the course of 
the experiment the iSODm functionalized PEDOT/GO samples showed a 72% decrease in the 
amount of super-oxide generated compared to non-functionalized PEDOT/GO.  Linear 
regression of the data in Fig. 4-4 revealed a 12 fold decrease in the rate of cytochrome C 
reduction by super-oxide.  This suggest that the iSODm functionalized surface intervened by 
converting superoxide to less reactive groups. 
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Figure 4-6: Cytochrome C Assay. Percent change in absorbance of Cytochrome C, catalase, 
xanthine, xanthine oxidase solutions over time.  PEDOT/GO Mg samples with and without iSODm 
functionalization were soaked in the solution and removed for each absorbance measurement then returned 
to the solution. (* p<0.05) 
4.4.5 Bacteria Culture 
E. coli attachment and viability on PEG and iSODm functionalized PEDOT/GO substrates were 
compared to non-functionalized coatings after 12 hour incubation period. PEG functionalized 
surfaces showed a significant 54% decrease in cell attachment.  Despite reducing cell 
attachment, the PEG functionalized surfaces did not show a significant decrease in the viability 
of the attached cells (Fig. 4-5B).  iSODm functionalized surfaces also showed a significant 46% 
decrease in the number of E. coli attached after 12 hours.   iSODm functional surfaces also 
showed an 8.5% decrease in the viability of those cells that did attach  This toxicity is likely 
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derived from the amine functional groups added to the iSODm which can disrupt the membranes 
of bacteria[374].  
 
 
Figure 4-7: E coli attachment and viability. (A) Total cell count of adhered bacteria to PEDOT/GO 
functionalized Mg. (B) viability of the attached cells. (* p <0.05) 
4.5 DISCUSSION 
Surface functionalization provides the ability to tailor the PEDOT/GO coating to fit a variety of 
needs which could be useful for improving Mg implant performance including; anti-bacterial, 
anti-inflammatory, and promoting tissue specific responses from the cells local to the implant 
surface.  To functionalize the surface of the PEDOT/GO coating, EDC-NHS chemistry was used 
covalently linking primary amines of the functionalizing molecule to the carboxylic acid groups 
of the exposed GO sheets exposed at the surface of the PEDOT/GO film[103].  
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EDC-NHS linking chemistry normally takes place in an aqueous solution, often at 
physiological or acidic pH[375, 376].  While the PEDOT/GO coating can act as initial barrier 
minimize corrosion upon immersion into phosphate buffers at physiological pH, the protection is 
less in acidic media due to the ionizing power driving rapid corrosion.  To minimize the effect of 
the EDC-NHS chemistry on the coated Mg sample, alternate solvents were investigated.  
Replacing the aqueous media while resulting in decreased corrosion may also result in a decrease 
in the rate of hydrolysis of the EDC[377].  This would consequently reduce the surface 
functionalization rate.  Nam et al showed that EDC-NHS crosslinking chemistry occurred 
optimally in a water and ethanol co-solvents with a mole ration of 0.12:1(ethanol:water) [377]. 
Various concentrations from 100% ethanol to the reported optimal ratio reported by Nam et al 
were investigated. Functionalization occurred effectively when using 1:1 (ethanol:water), which 
could be a result of the high EDC-NHS concentrations compensating somewhat for the slower 
reaction speed.    
The EDC-NHS covalent attachment method was confirmed through the attachment of 
fluorescently tagged albumin proteins.    Proteins have multiple primary amines located at the N-
terminus of each poly peptide chain as well as on amino acids lysine, asparagine, and glutamine, 
which can participate in the covalent linkage.  These amines facilitate attachment to the –COOH 
of the GO edges exposed at the surface of the PEDOT/GO film[103].  Effective attachment of 
these fluorescently tagged proteins suggests that the EDC-NHS reaction in 50% ethanol was 
sufficient to drive the surface functionalization of the PEDOT/GO films and facilitate covalent 
attachment of amine containing molecules.  
EDC-NHS chemistry was also used to attach of an amine functionalized PEG.  PEG is a 
versatile molecule in that it has been shown to decrease attachment of bacteria and fungi in 
 113 
addition to being antithrombogenic[168, 378, 379].  The PEG functionalized surface was tested 
for its ability to prevent both bacteria and mammalian cells from attaching.   
E coli bacteria adhesion was tested to determine if PEG functionalized PEDOT/GO had 
the ability to decrease bacterial attachment.  Low bacterial attachment is an important factor for 
medical implants as bacterial growth on the implant and subsequent patient infection can often 
require the premature removal of the device.  Previously PEG functionalized surfaces have been 
shown to prevent bacterial attachment[323, 378]. PEG functionalized PEDOT/GO surfaces 
showed a significant 47% decrease in the attachment of E coli (Fig. 4-5).  While significant, this 
decrease is not as dramatic as previously reported 80% decrease in bacterial adhesion following 
PEG functionalization [378] , these data suggest the PEG functionalized PEDOT/GO coating 
may be an effective method to minimize bacterial infection risk of Mg implants.  
 Attachment of PEG to the surface is reliant on exposed edges of GO protruding from the 
PEDOT/GO surface.  As shown in Fig. 2-2 C and 3-1 C, the edges of the GO sheets protrude 
from the surface of the PEDOT leaving exposed areas of PEDOT between the protruding sheets.  
In these PEDOT areas without exposed GO, there would be no PEG functionalization.  The 
small size of e coli (~0.5 µm diameter and ~ 2um length) could allow for their attachment in 
these exposed PEDOT locations resulting in an increase in attachment when compared to 
literature values for the decrease in bacterial attachment afforded by PEG coatings. 
In addition to bacterial adhesion, PEG functionalized PEDOT/GO films were tested for 
their ability to prevent attachment of fibroblasts.  Fibroblasts play an important role in the wound 
healing process and contribute to the fibrous tissue encapsulation that is synonymous with the 
FBR[380].  By preventing fibroblast attachment to the surface of the implant, the amount of 
fibrous tissue that forms around the implant could potentially be decreased.  PEG functionalized 
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surfaces showed a significant decrease in the number of fibroblasts adhered to the surface 
following 24 hr incubation as indicated by Live/Dead staining in Fig. 4-2.  This prevention of 
cell attachment is likely due to multiple factors.  Firstly, PEG results in the surface being more 
hydrophilic.  Hydrophilic surfaces decrease protein attachment through the formation of an 
interfacial layer of water molecules that are tightly bound to the surface[381], and non-specific 
protein adhesion, from the culture media in this case,  is the initial necessary step for cell 
attachment.  In addition to the prevention of protein adsorption and binding, the mobility of PEG 
chains around a single bonding point as well as the absence of ionic interactions with incoming 
cells may also prevent cellular attachment[379].   
The more complete prevention of fibroblast attachment compared to E. coli attachment 
could be due to the distribution of GO, and consequently functional groups, on the surface of the 
PEDOT/GO film.  The size of fibroblasts are reported at ~15 µm[382] while e coli have a 
diameter of ~0.5 µm and length of ~ 2um.  This smaller size could allow the e coli to infiltrate 
the PEG surface while the larger size of the fibroblasts may result in the level of PEG 
functionalization being sufficient to prevent attachment.    
While preventing the attachment of bacteria and certain cells is important for implants, 
attachment and guidance of other cell types could improve tissue interaction with the implant.  
PEDOT/GO surfaces functionalized with NGF were evaluated for their ability to guide PC12 cell 
neurite sprouting.  PC12 cells are rat phaeochromocytoma cells which closely resemble neurons 
and have a broad set of past research in use as a neuron model for studying the exocytosis of 
neural signaling[383].  PC12 cells also have a characteristic response to NGF exposure in that 
they sprout neurites and begin forming synapses with one another and can even develop neural 
networks[384-387].   Immobilization of NGF on other substrates has been shown to promote 
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neurite outgrowth and gradients of NGF can even guide neurite direction[388-390].  Following 
EDC-NHS functionalization of PEDOT/GO Mg with NGF, PC12 cells showed neurite sprouting 
and growth over four days(Fig. 4-4).  After 24 hours minimal neurite sprouting was visible, 
following 48 hours, neurites could be seen sprouting from the cells, and after 4 days, cells 
showed multiple neurites sprouting as well as increased neurite length (Fig. 4-4).  SEM images 
also revealed increased cell spreading and neurite extension on NGF functionalized samples 
(Fig. 4-5).  These results indicate that the functionalization of PEDOT/GO can be used guide the 
behavior of specific cells, and could be used for other biologics. 
The immobilization of a novel anti-inflammatory component iSODm (MnIIITEA-2-
Pyp5+(manganese(III)-5,10,15,20-tetrakis(N-(2-aminoethyl)pyridinium-2-yl)porphyrin))), 
developed in our lab, was also tested.  This molecule consists of a metalloporphyrin core that 
facilitates the catalytic reduction and oxidation of the superoxide to less harmful molecular 
oxygen and H2O2.  It accomplishes this by having a redox potential of (E1/2 = 230 mV vs. NHE) 
which lies roughly halfway between the oxidation (-160 mV) and reduction (890 mV) of superoxide.  
Additionally, four amine functional groups were added to the periphery which did not show an 
effect on the catalysis of superoxide to less harmful components[371]. These added amines allow 
iSODm to be immobilized on to the surface through EDC-NHS chemistry.  Reactive oxygen 
species (ROI), like superoxide, have been implicated in the foreign body response as being 
released by macrophages and foreign body giant cells in their “frustrated phagocytosis” phase as 
they try to degrade the implant[391]. High concentrations of ROS cause inflammation and cell 
death, iSODm serves to eliminate the harmful superoxide molecules around the implant through 
its catalytic reduction and oxidation of superoxide into molecular oxygen and hydrogen peroxide 
making the environment surrounding the implant more hospitable to healthy tissue.       
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iSODm activity following immobilization was quantified using xanthine and xanthine 
oxidase to generate superoxide, and cytochrome C to quantify the amount of superoxide 
generated. The iSODm on the surface catalyzes the reduction and/or oxidation of superoxide 
preventing it from reducing the cytochrome C.  iSODm functionalized PEDOT/GO samples 
soaked in the reaction solution showed a 12 fold decrease rate of superoxide generation 
indicating that the attached iSODm is active on the surface(Fig. 4-6).  This iSODm surface 
treatment could be used to improve the environment around implanted Mg devices by decreasing 
the concentration of superoxide local to the implant, which could allow healthy tissue to more 
easily interact with the implant. 
iSODm functionalized surfaces also resulted in a decrease in the viability of E. coli plated 
on the surface (Fig. 4-7).  This is likely due to the presence of multiple amine terminated 
functional groups on the iSODm.  While some of these amine functional groups are utilized for 
the covalent attachment to the PEDOT/GO surface, it is expected that others would be free to 
interact with the Bacteria.  Cationic antimicrobial agents, like amine, have kill bacteria through 
adsorption and penetration of the cell wall resulting in membrane disruption and leakage of 
intracellular material followed by degradation of proteins and nucleic acids[374].  Here it is 
likely that the exposed amine groups of the iSODm serve to kill the bacteria that have adhered to 
the surface through this membrane disruption mechanism.  This antimicrobial property could be 
useful for minimizing bacterial colonization of implanted medical devices.  These data suggest 
that iSODm surface functionalization has the potential to both decrease bacterial adhesion to the 
implant surface as well as continually improve the environment around the implant by mitigating 
superoxide to better facilitate the interaction of healthy tissue with the implant.   
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4.6 CONCLUSION 
Biological proteins, synthetic polymer, and small molecule compounds have all been 
successfully immobilized on the PEDOT/GO surface via a modified EDC-NHS chemistry. PEG 
functionalized surfaces showed a decrease in the attachment of fibroblasts, which contribute to 
fibrous tissue encapsulation around implants.  NGF functionalized surfaces supported the 
sprouting of neurites from PC12 cells.  iSODm functionalized PEDOT/GO decreased super 
oxide concentrations and decreased the viability of attached bacteria.  These results demonstrate 
that the PEDOT/GO coating is a versatile platform for surface immobilization, which could 
guide tissue.  Future work in designing applications with specific functionalization goals could 
use this study to guide their efforts.      
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5.0  CONCLUSION 
5.1 SUMMARY OF RESULTS 
This dissertation describes the development of a conducting polymer graphene oxide (GO) 
composite coating on magnesium and the investigation of this coating’s ability to delay 
corrosion, add drug releasing properties, and provide surface functionalization for magnesium 
implants.  In Chapter 2 the conducting polymer poly 3,4-ethylene dioxythiophene (PEDOT) was 
electropolymerized on Mg in the presence of GO resulting in a PEDOT/GO composite film.  
Electropolymerization was conducted in an ethanol based solution that minimizes the corrosion 
of the underlying Mg.  The resulting PEDOT/GO film displayed uniform coverage of the Mg 
substrate as well as a rough surface morphology resulting from the GO sheets at the surface of 
the film.  Tafel scans of the PEDOT/GO coated Mg displayed decreased corrosion current and a 
noble shift in the corrosion potential when compared to untreated Mg, both indicating the 
PEDOT/GO coating improved corrosion resistance.  During long term corrosion analysis, the 
PEDOT/GO coated Mg exhibited decreased production of three Mg corrosion byproducts, Mg2+, 
OH-, and H2.  In addition to assessing corrosion byproducts, electrochemical analysis 
investigated the electrode electrolyte interface at the surface of the Mg.  PEDOT/GO coated 
samples showed an increased resistance to corrosion throughout the long term corrosion 
experiment indicated by both electrochemical impedance spectroscopy (EIS) data as well as 
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equivalent circuit analysis.  Scanning electron microscope analysis post corrosion revealed a 
distinct morphology difference between uncoated Mg and Mg exposed beneath PEDOT/GO 
coatings.  Uncoated Mg displayed an amorphous morphology post corrosion while areas of Mg 
exposed beneath the PEDOT/GO coating showed a scale like morphology.  Elemental analysis 
through Energy Dispersive X-ray Spectroscopy indicated the uncoated Mg samples were 
predominantly covered in a Mg(OH)2 layer, while a magnesium phosphate layer was formed on 
the Mg exposed beneath the PEDOT/GO coating.  PEDOT/GO corrosion protection is attributed 
to initially acting as a barrier layer, followed by electrochemical coupling of the PEDOT/GO to 
Mg corrosion to generate a more protective magnesium phosphate layer.  The corrosion 
protection afforded by the PEDOT/GO also served to improve the neuronal biocompatibility of 
the Mg. Primary neuron viability was significantly improved for cells exposed to PEDOT/GO 
Mg corrosion media when compared to culture media exposed to uncoated Mg samples.  These 
results suggest that the PEDOT/GO coating is effective at decreasing Mg corrosion through its 
barrier properties as well as its redox coupling, and that this protection afforded improved 
biocompatibility. 
 In Chapter 3 the PEDOT/GO coating previously developed was tested for its ability to 
serve as a drug releasing platform.  Anti-inflammatory drug Dexamethasone (Dex) was 
incorporated into the film during polymerization resulting in a PEDOT/GO/Dex film.  This 
PEDOT/GO/Dex film exhibited similar, albeit less significant that PEDOT/GO alone, abilities to 
prevent corrosion suggesting that the redox coupling described in Chapter 2 was maintained but 
the barrier properties were diminished due to the addition of Dex.  The PEDOT/GO/Dex film 
displayed an ability to release Dex through externally powered reduction of the film.  
Additionally, Dex release was accomplished through the use of current generated during Mg 
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corrosion whereby increasing the area of exposed Mg increased the corrosion current and drove 
increased Dex release.  Dex bioactivity following release from PEDOT/GO/Dex films was also 
confirmed through the quenching of activity of microglia derived cells upon exposure to 
bacterial lipopolysaccharide.  Chapter 3 describes the use of the PEDOT/GO film as a 
combination corrosion inhibiting and a smart self-powered drug releasing platform that could be 
utilized to both control corrosion and affect tissue around Mg implants. 
Chapter 4 explored the ability of PEDOT/GO films, developed in Chapter 2, to be 
utilized as a method of adding biofunctional surface cues on to Mg.  Here, edges of the GO 
sheets are exposed at the surface of the PEDOT/GO film, which reveals the carboxylic acid 
groups of the GO.  These carboxyl groups were functionalized using carbodiimide crosslinking 
chemistry facilitating the addition of components with primary amines forming an amide bond.  
Functionalization was confirmed through the attachment of fluorescently tagged albumin protein 
that remained only on the functionalized samples following rinsing.  Additionally, amine 
terminated polyethylene glycol functionalization of PEDOT/GO on Mg decreased the attachment 
of both Escherichia coli bacteria and NIH-3T3 fibroblast cells.  Attachment of nerve growth 
factor to the surface of PEDOT/GO facilitated increased neurite sprouting of PC12 cells 
suggesting that the functionalization protocol can be utilized for driving specific cellular 
responses that may improve implant tissue interactions.  This work suggests that the PEDOT/GO 
coating can be a versatile method for adding functional groups on the surface of Mg to better 
guide tissue regeneration around the implant. 
This dissertation explored the ability to utilize a novel PEDOT/GO composite coating for 
improving Mg performance for implantable devices.  The PEDOT/GO coating decreased 
corrosion through unique electrochemical coupling with the underlying Mg, and improved 
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biocompatibility of Mg when exposed to primary neurons.  Additionally, Dex incorporation into 
the PEDOT/GO film provided a self-powered drug release mechanism.  Lastly, the edges of the 
GO sheets exposed at the surface of the PEDOT/GO film provided functional groups for the 
immobilization of bioactive molecules.  These results suggest that the PEDOT/GO coating could 
be a versatile platform for improving corrosion resistance and adding of bioactive cues to Mg for 
improving performance as an implantable material.        
5.2 FUTURE DIRECTIONS 
Chapter 2 illustrated a mechanism by which the PEDOT/GO coating could improve Mg 
corrosion resistance in a phosphate buffered solution.  The PEDOT/GO film described was 
polymerized to a total charge of 10 mC and in a 10 mg/ml GO solution.  Future work could 
investigate the potential of altering both the total charge used during electropolymerization as 
well as the concentration of GO in the film.  Altering the total charge would result in a change in 
the thickness of the PEDOT/GO film from the current 50 μm and presumably a change in the 
corrosion protection afforded by the film.  Similarly, altering the concentration of GO in the film 
could not only change the barrier properties of the film, but also result in changes in surface 
morphology and corrosion protection due to the entrapped GO providing added negative charges 
which prevent negatively charged ions from reaching the underlying Mg surface.  A detailed 
investigation into the role of polymer thickness and GO concentration and their effects on 
corrosion resistance would provide a framework for the ability to design of the PEDOT/GO 
coating to meet the needs of the different Mg implant applications.  This improved corrosion rate 
modulation would allow for the PEDOT/GO coating to be tuned so as to prevent degradation for 
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the specific duration required for tissue healing.  Following the appropriate healing during, the 
implant could then begin to degrade. 
In addition, future work may look towards improving the degradability of the 
PEDOT/GO coating.  While literature suggests conducting polymers are biocompatible and that 
GO can be degraded in vivo, potential issues may arise as pieces of the PEDOT/GO coating 
delaminate during corrosion of the underlying Mg.  To address these issues, degradable 
conducting polymers [392] may be investigated.  To that end, our lab has begun research with 
degradable conducting polymers developed in conjunction with outside industrial partners.   
The effects of the coating thickness and GO concentration on the mechanical properties 
of the film may also be investigated to minimize potential shedding of the polymer film.  The 
current PEDOT/GO film protocol results in a film that while well adhered to the surface, is 
relatively brittle.  This is likely due to the high concentration of GO in the film.  Improving the 
flexibility of the film could minimize potential complications from delamination as well as 
improve the longevity of the film in vivo. 
    Chapter 3 Investigated the ability to use corrosion current generated by Mg oxidation 
to drive drug release from the PEDOT/GO film.  This work only investigated dexamethasone 
release.  In the future, other anti-inflammatory molecules as well as tissue specific molecules 
such as bisphosphonate molecules for orthopedic applications[301] and Sirolimus and Paclitaxel 
for stent applications could be investigated.  Multi-layer techniques using a layer of PEDOT/GO 
without drug followed by a topcoat of PEDOT/GO with drug could also be investigated as a way 
to improve the corrosion resistance of the self-powered drug releasing system. In addition, 
further investigation into the correlation of exposed Mg and its effect on the drug release profile 
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could improve the ability to tune the drug release profile for the needs of each tissue and the 
specific drug being released. 
Chapter 4 provided an initial exploration into the ability to surface functionalize the 
PEDOT/GO Mg surface with bioactive cues.  While this work suggests that the PEDOT/GO 
coating could serve as an effective method for immobilizing bioactive cues, more 
characterization and optimization need to be conducted prior to initiating in vivo testing.  A more 
detailed analysis of the binding and coverage of the bound moiety should be conducted using 
Fourier Transform Infrared Spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS).  
This analysis would allow for a better understanding of the method of attachment and coverage 
required to elicit a biologic response.  This type of surface analysis would likely be required for 
each specific moiety attached to the surface.  Analysis in this way could also allow for further 
optimization of the coating protocol to maximum tissue response as well as retain maximum 
bioactivity of the functionalized moiety. 
Lastly, the combination of corrosion protection, drug release, and surface 
functionalization through PEDOT/GO coatings could be analyzed.  This work largely focused on 
each component individually with the intent to bolster the basic knowledge so as to allow for the 
future development of coatings.  Using methods outlined in this work future investigation into 
the use of a single coating that provides improved corrosion resistance, decreased hydrogen 
evolution, self-powered drug release, and a method to add surface cues could be used to improve 
Mg implant performance. 
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